<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Rev (2021)</journal-id><journal-id journal-id-type="iso-abbrev">Med Rev (2021)</journal-id><journal-id journal-id-type="pmc-domain-id">4405</journal-id><journal-id journal-id-type="pmc-domain">medrev</journal-id><journal-id journal-id-type="publisher-id">mr</journal-id><journal-title-group><journal-title>Medical Review</journal-title></journal-title-group><issn pub-type="ppub">2097-0773</issn><issn pub-type="epub">2749-9642</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10471115</article-id><article-id pub-id-type="pmcid-ver">PMC10471115.1</article-id><article-id pub-id-type="pmcaid">10471115</article-id><article-id pub-id-type="pmcaiid">10471115</article-id><article-id pub-id-type="pmid">37724086</article-id><article-id pub-id-type="doi">10.1515/mr-2022-0047</article-id><article-id pub-id-type="publisher-id">mr-2022-0047</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Progress in nanoparticle-based regulation of immune cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names initials="YN">Ya-Nan</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="G">Gui</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yue</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ye</surname><given-names initials="QN">Qian-Ni</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="YQ">Yi-Qun</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_003" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="S">Song</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yang</given-names></name><xref rid="j_mr-2022-0047_aff_004" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-6291-5711</contrib-id><name name-style="western"><surname>Xu</surname><given-names initials="CF">Cong-Fei</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:xucf@scut.edu.cn">xucf@scut.edu.cn</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-9957-9208</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="J">Jun</given-names></name><xref rid="j_mr-2022-0047_aff_001" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_002" ref-type="aff"/><xref rid="j_mr-2022-0047_aff_005" ref-type="aff"/><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:mcjwang@scut.edu.cn">mcjwang@scut.edu.cn</email></contrib><aff id="j_mr-2022-0047_aff_001">
<institution content-type="dept">School of Biomedical Sciences and Engineering</institution>, <institution content-type="university">South China University of Technology, Guangzhou International Campus</institution>, <city>Guangzhou</city>, <state>Guangdong Province</state>, <country country="CN">China</country>
</aff><aff id="j_mr-2022-0047_aff_002">
<institution content-type="dept">National Engineering Research Center for Tissue Restoration and Reconstruction</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city>, <state>Guangdong Province</state>, <country country="CN">China</country>
</aff><aff id="j_mr-2022-0047_aff_003">
<institution content-type="dept">Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city>, <state>Guangdong Province</state>, <country country="CN">China</country>
</aff><aff id="j_mr-2022-0047_aff_004">
<institution content-type="dept">Department of Biomedical Engineering</institution>, <institution content-type="university">Wake Forest School of Medicine</institution>, <city>Winston-Salem</city>, <state>NC</state>, <country country="US">USA</country>
</aff><aff id="j_mr-2022-0047_aff_005">
<institution content-type="dept">Guangdong Provincial Key Laboratory of Biomedical Engineering</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city>, <state>Guangdong Province</state>, <country country="CN">China</country>
</aff></contrib-group><author-notes><corresp id="cor1"><bold>Corresponding authors: Cong-Fei Xu</bold>, <institution content-type="dept">School of Biomedical Sciences and Engineering</institution>, <institution content-type="university">South China University of Technology, Guangzhou International Campus</institution>, <city>Guangzhou</city><addr-line>511442</addr-line>, <state>Guangdong Province</state>, <country country="CN">China</country>; and <institution content-type="dept">National Engineering Research Center for Tissue Restoration and Reconstruction</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city><addr-line>510006</addr-line>, Guangdong Province, China, E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:xucf@scut.edu.cn">xucf@scut.edu.cn</email>; and <bold>Jun Wang</bold>, <institution content-type="dept">School of Biomedical Sciences and Engineering</institution>, <institution content-type="university">South China University of Technology, Guangzhou International Campus</institution>, <city>Guangzhou</city><addr-line>511442</addr-line>, <state>Guangdong Province</state>, <country country="CN">China</country>; <institution content-type="dept">National Engineering Research Center for Tissue Restoration and Reconstruction</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city><addr-line>510006</addr-line>, <state>Guangdong Province</state>, <country country="CN">China</country>; and <institution content-type="dept">Guangdong Provincial Key Laboratory of Biomedical Engineering</institution>, <institution content-type="university">South China University of Technology</institution>, <city>Guangzhou</city><addr-line>510006</addr-line>, <state>Guangdong Province</state>, <country country="CN">China</country>, E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:mcjwang@scut.edu.cn">mcjwang@scut.edu.cn</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>4</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>4</month><year>2023</year></pub-date><volume>3</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">444433</issue-id><fpage>152</fpage><lpage>179</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>18</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-12 14:25:09.770"><day>12</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 the author(s), published by De Gruyter, Berlin/Boston</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>the author(s), published by De Gruyter, Berlin/Boston GmbH, Berlin/Boston</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="mr-3-2-mr-2022-0047.pdf"/><abstract><title>Abstract</title><p>Immune cells are indispensable defenders of the human body, clearing exogenous pathogens and toxicities or endogenous malignant and aging cells. Immune cell dysfunction can cause an inability to recognize, react, and remove these hazards, resulting in cancers, inflammatory diseases, autoimmune diseases, and infections. Immune cells regulation has shown great promise in treating disease, and immune agonists are usually used to treat cancers and infections caused by immune suppression. In contrast, immunosuppressants are used to treat inflammatory and autoimmune diseases. However, the key to maintaining health is to restore balance to the immune system, as excessive activation or inhibition of immune cells is a common complication of immunotherapy. Nanoparticles are efficient drug delivery systems widely used to deliver small molecule inhibitors, nucleic acid, and proteins. Using nanoparticles for the targeted delivery of drugs to immune cells provides opportunities to regulate immune cell function. In this review, we summarize the current progress of nanoparticle-based strategies for regulating immune function and discuss the prospects of future nanoparticle design to improve immunotherapy.</p></abstract><kwd-group><title>Keywords</title><kwd>biomaterial</kwd><kwd>drug delivery</kwd><kwd>immune cell</kwd><kwd>immunotherapy</kwd><kwd>nanoparticle</kwd></kwd-group><funding-group><award-group award-type="grant" id="award-grp1"><funding-source>Guangdong Basic and Applied Basic Research Foundation</funding-source><award-id>2022B1515020025</award-id></award-group><award-group award-type="grant" id="award-grp2"><funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://dx.doi.org/10.13039/501100001809">National Natural Science Foundation of China</funding-source><award-id>32271442</award-id><award-id>52130301</award-id><award-id>82072048</award-id></award-group><award-group award-type="grant" id="award-grp3"><funding-source>National Key R&amp;D Program of China</funding-source><award-id>2022YFB3808100</award-id></award-group><award-group award-type="grant" id="award-grp4"><funding-source>Fundamental Research Funds for the Central Universities</funding-source><award-id>2022ZYGXZR102</award-id></award-group><award-group award-type="grant" id="award-grp5"><funding-source>Science and Technology Program of Guangzhou, China</funding-source><award-id>202103030004</award-id></award-group></funding-group><counts><fig-count count="010"/><table-count count="000"/><ref-count count="200"/><page-count count="028"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="j_mr-2022-0047_s_001"><title>Introduction</title><p>The immune system consists of immune cells, related molecules, and tissues that protect the body from external influences and maintain homeostasis. It maintains a dynamic balance between promoting immune or inflammatory processes and regulating or inhibiting functions, playing a crucial role in tissue homeostasis and disease progression&#160;[<xref rid="j_mr-2022-0047_ref_001" ref-type="bibr">1</xref>]. Immunomodulatory biomaterials capable of manipulating innate and adaptive immunity hold great promise for many preventive and therapeutic purposes&#160;[<xref rid="j_mr-2022-0047_ref_002" ref-type="bibr">2</xref>]. Nanotechnology enables engineered nanomaterials to target specific organs or tissues and deliver immunomodulators while avoiding adverse immunosuppressive or immunostimulatory effects. Various nanomaterials are in clinical trials or have been approved by the US Food and Drug Administration (FDA)&#160;[<xref rid="j_mr-2022-0047_ref_003" ref-type="bibr">3</xref>,&#160;<xref rid="j_mr-2022-0047_ref_004" ref-type="bibr">4</xref>].</p><p>Nanoparticles can modulate the immune system for different therapeutic purposes (inflammation, autoimmune disorders, tumors). For example, when immune cell function is suppressed by stress, chronic infection or uncontrolled due to autoimmune disease, allergies, transplants, and hypersensitivity reactions, nanoparticles can be used as immunomodulators to modulate immunosuppression or activation. Immunosuppressive nanoparticles can block the adverse immune response (autoimmune or allergic disease). In contrast, immunoreactive nanoparticles can transport cytokines and molecules that enhance the immune response (useful for treatment in immunosuppressed patients)&#160;[<xref rid="j_mr-2022-0047_ref_005" ref-type="bibr">5</xref>]. Nanoparticles for tumor immunotherapy and adjuvant nanoparticles for improved vaccines have also been developed&#160;[<xref rid="j_mr-2022-0047_ref_006" ref-type="bibr">6</xref>]. For example, the innate immune response can kill tumor cells through macrophages, natural killer cells, neutrophils, and dendritic cells (DCs). Tumor-associated antigens stimulate the maturation and subsequent migration of DCs to the lymph nodes. Once in the lymph nodes, it stimulates T&#160;cell activation (the adaptive immune system), then the activated T&#160;cells migrate and recognize tumor cell antigens. Finally, tumor cells are killed by cytotoxic T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_007" ref-type="bibr">7</xref>].</p><p>To regulate immune cell function, nanocarriers can be applied via several approaches. (1) Nanoparticle as adjuvants can be used to alter the response of immune cell subsets. The adjuvant activity of nanoparticles depends on their physicochemical properties, and their ability to be internalized by different cells can modulate the degree of immune cell activation. (2) Nanoparticles can deliver drugs into immune cells. The delivery of immunomodulatory molecules via nanoparticles to stimulate the immune response may limit systemic toxicity. The characteristics of the nanocarriers (i.e.,&#160;size, surface charge, or shape) can be optimized to facilitate binding to immune cells, and specific immune cell populations preferentially take up different modifications (e.g., mannose modification). Cell-specific activation and selective identification can only be achieved using actively targeted ligands. (3) Nanoparticles can be used to deliver immunomodulators to the surface of immune cells. They can block or activate signaling pathways mediated by relevant ligands and enhance the interaction between effector and target cells to regulate immune cell function.</p><p>Here we discuss the role of immune cells in the initiation and progression of various diseases, summarize the leading strategy used to regulate immune cells, and review drug delivery systems designed to target immune cells. Finally, we provide a prospectus of the future of immune cell-targeted drug delivery systems.</p></sec><sec id="j_mr-2022-0047_s_002"><title>Relationship between immune cells and diseases</title><p>Abnormal immune responses, including excess immune suppression or activation, will inevitably lead to disease development. Recent studies have shown that the presence of both inflammatory processes (immune stimulation) and immune tolerance (no response to autoantigens or harmless foreign antigens) are influenced by the way antigens are presented&#160;[<xref rid="j_mr-2022-0047_ref_008" ref-type="bibr">8</xref>]. When the mechanisms that regulate the balance between pathogen recognition and self-injury avoidance are compromised, inflammation can get out of control, resulting in sustained immune activation and tissue lesions.</p><sec id="j_mr-2022-0047_s_002_s_001"><title>Role of innate immunity in diseases</title><p>The innate immune system, consisting of physical mucosal barriers, proteins, and myeloid cells (including granulocytes, mast cells, monocytes, macrophages, DCs, and innate lymphoid cells), is the first line of defense against infectious agents and other environmental challenges. These cells initiate adaptive immune responses such as phagocytosis of macrophages and granulocytes and cytotoxicity of NK cells while producing effector responses. Through the opsonization of antibodies, innate immune cells also participate in the effect-response after antibody induction through antibody-dependent cytophagocytosis or antibody-dependent cytotoxicity and secrete specific cytokines at the reaction site to produce local inflammation&#160;[<xref rid="j_mr-2022-0047_ref_009" ref-type="bibr">9</xref>&#8211;<xref rid="j_mr-2022-0047_ref_011" ref-type="bibr">11</xref>]. For example, autoimmune diseases are chronic inflammatory diseases caused by immune dysregulation. DCs are directly involved in systemic autoimmune responses and disease as antigen-presenting cells and major producers of type 1 interferon&#160;[<xref rid="j_mr-2022-0047_ref_012" ref-type="bibr">12</xref>]. Different subpopulations of DCs regulate humoral and cellular adaptive immunity&#160;[<xref rid="j_mr-2022-0047_ref_013" ref-type="bibr">13</xref>]. Immunosuppressive factors in tumors also inhibit innate immune cells from maintaining an effective antitumor immune response. Infiltration of myeloid suppressor cells (MDSCs) or tumor-associated macrophages (TAMs) into a tumor may create a tolerant environment that inhibits antitumor immune activity, thereby protecting the continued growth of tumor cells. Excess circulating MDSCs and tumor-infiltrating MDSCs or TAMs have been associated with poor prognosis in various cancers&#160;[<xref rid="j_mr-2022-0047_ref_014" ref-type="bibr">14</xref>, <xref rid="j_mr-2022-0047_ref_015" ref-type="bibr">15</xref>].</p></sec><sec id="j_mr-2022-0047_s_002_s_002"><title>Role of adaptive immunity in diseases</title><p>The adaptive immune response follows the innate immune response via the activation of T and B lymphocytes, antigen-specific cells that target pathogens and immune system initiators. The two immune responses are interrelated and highly dependent on immune system activation&#160;[<xref rid="j_mr-2022-0047_ref_016" ref-type="bibr">16</xref>]. T&#160;cells and B&#160;cells are the main and central force in mediating the adaptive immune response, but in some diseases, such as chronic inflammation and tumors, T&#160;cells become dysfunctional due to multiple inhibitory signals in the inflammatory microenvironment&#160;[<xref rid="j_mr-2022-0047_ref_017" ref-type="bibr">17</xref>]. Prolonged exposure of T&#160;cells to homologous antigens leads to T&#160;cell receptor (TCR) signaling, resulting in sustained elevated expression of inhibitory receptors on these cells. In addition, T&#160;cells enter a state of dysfunction characterized by graded loss of effector function and proliferation and different transcriptional and metabolic changes&#160;[<xref rid="j_mr-2022-0047_ref_019" ref-type="bibr">18</xref>]. Upregulation of immune checkpoints has been described as a marker of T&#160;cell depletion, a secondary characteristic of which is the progressive loss of effector function, including secretion of interleukin 2 (IL-2) and tumor necrosis factor &#945; (TNF-&#945;)&#160;[<xref rid="j_mr-2022-0047_ref_020" ref-type="bibr">19</xref>, <xref rid="j_mr-2022-0047_ref_021" ref-type="bibr">20</xref>]. B&#160;cells also play a key role in disease progression. For example, tumor-infiltrating B&#160;cells mediate humoral and cellular immunity in tumor tissue, but their role in antitumor immunity is still&#160;under debate&#160;[<xref rid="j_mr-2022-0047_ref_022" ref-type="bibr">21</xref>]. Some studies have shown that B&#160;cells&#160;induce and maintain beneficial antitumor activity. In contrast, others have found that B&#160;cells may perform tumor-suppressing functions due to their different immunosuppressive subtypes&#160;[<xref rid="j_mr-2022-0047_ref_023" ref-type="bibr">22</xref>].</p></sec></sec><sec id="j_mr-2022-0047_s_003"><title>Strategies and challenges for regulating immune cell function</title><p>For chronic inflammatory diseases, including tumors, the key is to reverse immune cell inhibition and incapacitating depletion, reactivate existing immune responses, or generate new antigen-specific immune responses. For example, immune checkpoint blockade therapy has yielded unprecedented efficacy in a variety of tumor diseases by blocking immune checkpoints, but immunotherapy (especially monotherapy) remains ineffective in most patients, a finding that reflects the heterogeneity of immunobiology and the complex mechanisms of immune escape in chronic inflammation&#160;[<xref rid="j_mr-2022-0047_ref_024" ref-type="bibr">23</xref>,&#160;<xref rid="j_mr-2022-0047_ref_025" ref-type="bibr">24</xref>]. Understanding the interactions between immune cells and the disease-associated microenvironment is crucial for analyzing the mechanisms of action and an effective strategy for improving the efficacy of current immunotherapies. We need a multi-pronged approach to induce an immune response, enhance the depth and persistence of the immune response, and achieve complete remission. Methods include (1) eliminating immunosuppression by weakening immunosuppressive mediators such as suppressive cells or blocking them via inhibitory receptors; (2) inducing immunogenic death of tumor cells (in combination with chemotherapy, radiotherapy, targeted therapy, and cell therapy); (3) enhancing antigen-presenting cell function (immune adjuvant); and (4) promoting the activation, enhancement, and survival of memory T&#160;cells and macrophage function.</p><p>Although immunotherapy improves outcomes for many patients by intervening in the immune system to treat various diseases, overstimulation can lead to autoimmune toxicity, also known as immune-related adverse events (irAEs). As a result, there remains a critical unmet need for alternative ways to drive the immune system response safely and effectively to targeting various diseases. The main challenge is to hit these targets safely at the right time and place&#160;[<xref rid="j_mr-2022-0047_ref_026" ref-type="bibr">25</xref>&#8211;<xref rid="j_mr-2022-0047_ref_028" ref-type="bibr">27</xref>].</p><p>To enable immune cell regulation, nanoparticles have emerged as a suitable vehicle to overcome the limitations of conventional pharmaceutical preparations and their associated pharmacokinetics. Various studies have reported that nanoparticles can regulate immune cell function&#160;[<xref rid="j_mr-2022-0047_ref_029" ref-type="bibr">28</xref>,&#160;<xref rid="j_mr-2022-0047_ref_030" ref-type="bibr">29</xref>]. The properties of the nanoparticle (e.g., composition, size, shape, surface chemical modifications, peptides, or protein modifications) determine the interaction between the nanoparticle and immune cells. Due to the presence of different cells and molecules in other organs, such as epithelial cells (e.g., DCs, macrophages) or blood (e.g., granulocytes, mononuclear/macrophages, lymphocytes), the results of immune stimulation vary. A better understanding of immune responses and their interactions with nanoparticles is critical to developing nanoparticle-based immunoregulatory therapies.</p></sec><sec id="j_mr-2022-0047_s_004"><title>Nanoparticle-based strategies for T&#160;cell regulation</title><p>T&#160;cells are one of the most important immune system lymphocytes and play an essential role in various diseases, including inflammation, cancers, and autoimmune diseases&#160;[<xref rid="j_mr-2022-0047_ref_031" ref-type="bibr">30</xref>]. T&#160;cells originate in the bone marrow and mature in the thymus&#160;[<xref rid="j_mr-2022-0047_ref_032" ref-type="bibr">31</xref>]. After migration to the thymus gland, the lymphoid precursors differentiate into helper CD4<sup>+</sup> T&#160;cells, cytotoxic CD8<sup>+</sup> T&#160;cells, regulatory CD4<sup>+</sup> T&#160;cells, or become memory T&#160;cells. Cytotoxic CD8<sup>+</sup> T&#160;cells can kill infected cells and cancer cells&#160;[<xref rid="j_mr-2022-0047_ref_018" ref-type="bibr">32</xref>]. CD4<sup>+</sup> T&#160;cells perform different functions depending on their effector subtypes, including activation of B lymphocytes, cytotoxic T&#160;cells, and the innate immune system&#160;[<xref rid="j_mr-2022-0047_ref_033" ref-type="bibr">33</xref>]. Here we review nanotechnology applied to T&#160;cells, including nanoparticle-mediated T&#160;cell activation, T cell-targeting strategies for nanoparticle delivery, CAR-T cell engineering, and nano-bispecific-engagers of T&#160;cells.</p><sec id="j_mr-2022-0047_s_004_s_001"><title>Nanoparticles for T&#160;cell activation</title><p>Activation and expansion are important for T&#160;cell function. T&#160;cell activation requires three signals: (1) recognition of the peptide/major histocompatibility complex (MHC) by TCR on the T&#160;cell surface; (2) co-stimulation signals induced by interactions between co-signaling molecules expressed on antigen-presenting cells (APCs) and their paired T cell-expressed receptors; and (3) cytokines such as IL-2, IL-12, and Type I IFN. Effective T&#160;cell activation remains a challenge in tumor therapy&#160;[<xref rid="j_mr-2022-0047_ref_034" ref-type="bibr">34</xref>]. Nanotechnology control of T&#160;cell activation offers solutions.</p><p>Artificial APC (aAPC) micro- or nanoparticle-based systems mimic natural APCs, mainly DCs, to activate adaptive immunity. To generate the three required activation signals, Cheung et&#160;al. developed fluid lipid bilayer-supported mesoporous silica micro-rods (MSRs) (<xref rid="j_mr-2022-0047_fig_001" ref-type="fig">Figure&#160;1A</xref>). The APC-MSRs contained anti-CD3 antibody for T&#160;cell attachment, pMHC for signal 1, &#945;CD28 antibody for signal 2, and cytokine IL-2 for signal 3. They induced 2- to 10-fold greater expansion of T&#160;cells than commercial expansion beads (Dynabeads)&#160;[<xref rid="j_mr-2022-0047_ref_035" ref-type="bibr">35</xref>]. Many biomaterials-based nanoscale aAPCs have been developed. Poly (lactic-co-glycolic acid) (PLGA)-based nanoparticles were functionalized with an MHC Class I-Ig fusion protein to mimic signal one and an agonistic monoclonal anti-CD28 antibody (<xref rid="j_mr-2022-0047_fig_001" ref-type="fig">Figure&#160;1B</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_036" ref-type="bibr">36</xref>]. Kosmides et&#160;al. showed that combining this polymeric aAPC and anti-PD-1 monoclonal antibody induced the greatest CD8<sup>+</sup> T&#160;cell activation <italic toggle="yes">in&#160;vitro</italic> and delayed melanoma tumor growth and extended survival <italic toggle="yes">in&#160;vivo</italic>. Lipid-based and inorganic materials can also mimic the features of APCs to activate T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_037" ref-type="bibr">37</xref>,&#160;<xref rid="j_mr-2022-0047_ref_038" ref-type="bibr">38</xref>]. Compared to micro-aAPCs, nano-aAPCs have a small contact area with T&#160;cells, leading to less efficient activation. To enhance the area of contact between the T&#160;cell and nano-aAPC, nanoparticle clustering and shape alternation have been applied to nano-aAPC design. Perica et&#160;al. showed that magnetic-field-induced nanoparticle clustering enhanced T&#160;cell activation&#160;[<xref rid="j_mr-2022-0047_ref_039" ref-type="bibr">39</xref>]. The magnetic field-mediated aggregation of nano-aAPCs increased TCR cluster size and T&#160;cell expansion <italic toggle="yes">in&#160;vitro</italic> and enhanced adaptive T&#160;cell immunotherapy (<xref rid="j_mr-2022-0047_fig_001" ref-type="fig">Figure&#160;1C</xref>). The cellular fate of nano-aAPCs can also be altered by changing their shape. Ellipsoid particles reduce non-targeted uptake and increase specific uptake, thereby enhancing anticancer efficacy&#160;[<xref rid="j_mr-2022-0047_ref_040" ref-type="bibr">40</xref>,&#160;<xref rid="j_mr-2022-0047_ref_041" ref-type="bibr">41</xref>]. Meyer et&#160;al. used ellipsoidal PLAG nano-aAPCs functionalized with an MHC Class I Ig dimer (signal 1) and anti-CD28 (signal 2) to reduce phagocytosis compared to spherical nano-aAPCs&#160;[<xref rid="j_mr-2022-0047_ref_042" ref-type="bibr">42</xref>]. The use of large nano-aAPCs is an effective way to increase the contact area with T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_043" ref-type="bibr">43</xref>]. Biomimetics such as cell membrane-based aAPCs provide natural protein structures that may facilitate conjugation to solid nanoparticles. Jiang et&#160;al. reported a tumor cell-derived membrane-coated aAPC to directly stimulate T&#160;cells without APCs&#160;[<xref rid="j_mr-2022-0047_ref_044" ref-type="bibr">44</xref>]. Wild-type B16 melanoma cells presenting antigen/MHC-I complex were engineered to co-express cytosolic OVA and costimulatory protein CD80. The membranes of these engineered tumor cells were then used to coat polymeric nanoparticles to generate aAPCs, which efficiently activated T&#160;cells <italic toggle="yes">ex vivo</italic> and significantly delayed tumor growth after intravenous injection (<xref rid="j_mr-2022-0047_fig_001" ref-type="fig">Figure&#160;1D</xref>). aAPCs can also be used to induce regulatory T&#160;cells. Immune-tolerant aAPCs were developed by coating nanoparticles with autoimmune disease-related peptides/MHC complex&#160;[<xref rid="j_mr-2022-0047_ref_045" ref-type="bibr">45</xref>,&#160;<xref rid="j_mr-2022-0047_ref_046" ref-type="bibr">46</xref>]. These aAPCs do not carry signal 2 for T&#160;cell activation and thus induce antigen-specific regulatory CD4<sup>+</sup> and CD8<sup>+</sup> T&#160;cells and antigen-specific immune tolerance for treating autoimmune disease.</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_001" orientation="portrait"><label>Figure&#160;1:</label><caption><p>Nano-aAPCs for T&#160;cell activation. (A) APC-ms prepared from MSRs can realize polyclonal T&#160;cell expansion and antigen-specific T&#160;cell expansion by binding different antibodies (image source: Li et&#160;al. [<xref rid="j_mr-2022-0047_ref_035" ref-type="bibr">35</xref>] with permission). (B) <italic toggle="yes">In vitro</italic> tumor microenvironment model system for MHC IgG dimer and anti-CD28 antibody-conjugated PLGA nanoparticles [<xref rid="j_mr-2022-0047_ref_036" ref-type="bibr">36</xref>]. (C) Nano-aAPC synthesis by coupling MHC-Ig dimers and costimulatory anti-CD28 to iron-dextran nanoparticles [<xref rid="j_mr-2022-0047_ref_039" ref-type="bibr">39</xref>]. (D) Engineered cancer cell-membrane-coated nanoparticles for direct antigen presentation [<xref rid="j_mr-2022-0047_ref_044" ref-type="bibr">44</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_001.jpg"/></fig></sec><sec id="j_mr-2022-0047_s_004_s_002"><title>Nanoparticles for T cell-targeting delivery</title><p>After injection, nanoparticles are easily captured by the mononuclear phagocyte system or tissue-resident phagocytes. Some studies have shown that, without targeting strategies, T&#160;cells may take up fewer nanoparticles than other immune cells like DCs&#160;[<xref rid="j_mr-2022-0047_ref_047" ref-type="bibr">47</xref>], [<xref rid="j_mr-2022-0047_ref_048" ref-type="bibr">48</xref>], [<xref rid="j_mr-2022-0047_ref_049" ref-type="bibr">49</xref>]. Therefore, nanoparticles with specific properties can be used for T&#160;cell delivery.</p><p>T&#160;cell delivery can be accomplished passively, mediated by the physical properties of the nanoparticles. Li et&#160;al. used cationic lipid-assisted polymeric nanoparticles encapsulating small interfering RNA (siRNA) targeting cytotoxic T&#160;lymphocyte-associated molecule-4 (CTLA-4) for T&#160;cell immunotherapy&#160;[<xref rid="j_mr-2022-0047_ref_050" ref-type="bibr">50</xref>]. This nanoparticle delivery system could deliver siRNA into CD4<sup>+</sup> and CD8<sup>+</sup> T&#160;cells <italic toggle="yes">in&#160;vivo</italic>, enhancing T&#160;cell activation and proliferation, enhancing the antitumor immune response, and significantly inhibiting B16 melanoma. Huq et&#160;al. reported antioxidant carbon nanoparticles for T&#160;cell delivery&#160;[<xref rid="j_mr-2022-0047_ref_051" ref-type="bibr">51</xref>]. Nontoxic poly (ethylene glycol)-functionalized hydrophilic carbon clusters (PEG-HCCs) are taken up by T&#160;cells over other splenic immune cells after systemic application <italic toggle="yes">in&#160;vivo</italic>. However, T&#160;cells in lymph nodes did not exhibit this preference. Hewitt et&#160;al. demonstrated that non-functionalized ultrasmall silica nanoparticles (USSNs, diameter 3.6&#8211;5.1&#160;nm) strongly activated T&#160;cells but showed no T cell-specific uptake&#160;[<xref rid="j_mr-2022-0047_ref_052" ref-type="bibr">52</xref>]. USSNs induced dose-dependent CD4<sup>+</sup> and CD8<sup>+</sup> T&#160;cell activation and INF-&#947; secretion but failed to induce secretion of IL-2, IL-10, IL-4, or T&#160;cell proliferation. Thiramanas et&#160;al. investigated the use of silica nanoparticles (SiNPs) of different particle sizes and physicochemical properties as T&#160;cell delivery vectors&#160;[<xref rid="j_mr-2022-0047_ref_053" ref-type="bibr">53</xref>] by varying size, core hydrophobicity, surface charge, and surface function to modulate CD8<sup>+</sup> T&#160;cell uptake and toxicity. Cellular uptake and toxicity are primarily size- and dose-dependent. SiNPs smaller than 100&#160;nm had a significant toxic effect. Another study of nanoparticle size and T&#160;cell delivery&#160;[<xref rid="j_mr-2022-0047_ref_054" ref-type="bibr">54</xref>] used a cationic deblock copolymer modified with triphenylphosphonium cations and small cationic nanohydrogel particles and tested them for siRNA delivery to T&#160;cells. Their nanoparticles achieved efficient complexation of siRNA and significant internalization into T&#160;cells without reducing cell viability <italic toggle="yes">in&#160;vitro</italic>.</p><p>T cell-targeting antibodies can functionalize nanoparticles to enhance T&#160;cell uptake. Anti-CD3 antibody-conjugated gelatin nanoparticles were developed for T cell-specific targeting&#160;[<xref rid="j_mr-2022-0047_ref_055" ref-type="bibr">55</xref>] by binding biotinylated anti-CD3 antibodies to nanoparticles via NeutrAvidin-biotin-complex formation. Uptake efficiency by T&#160;cell leukemia cells via endocytosis was about 84% <italic toggle="yes">in&#160;vitro</italic>. Kheirolomoon et&#160;al. also demonstrated that anti-CD3 antibody-conjugated lipid nanoparticles (&#945;CD3-LNPs) could be used for T&#160;cell delivery <italic toggle="yes">in&#160;vitro</italic> and <italic toggle="yes">in&#160;vivo</italic>&#160;[<xref rid="j_mr-2022-0047_ref_056" ref-type="bibr">56</xref>]. &#945;CD3-LNPs efficiently delivered mRNA to Jurkat T&#160;cells <italic toggle="yes">in&#160;vitro</italic> and, after systemic injection, &#945;CD3-LNPs encapsulating mCherry mRNA accumulated in the spleen. The efficiency of mCherry expression was 2%&#8211;4% of all splenic T&#160;cells and 2%&#8211;7% of all circulating T&#160;cells. Ramishetti et&#160;al. described a CD4-targeting strategy to deliver siRNAs specifically to CD4<sup>+</sup> T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_057" ref-type="bibr">57</xref>]. Anti-CD4 antibody-functionalized LNPs loaded with CD45 siRNA were taken up by CD4<sup>+</sup> T&#160;cells in the spleen, inguinal lymph nodes, blood, and bone marrow, resulting in significant knockdown of CD45 expression. Tombacz et&#160;al. also reported anti-CD4 antibody-conjugated LNPs to enable specific targeting of mRNA interventions in CD4<sup>+</sup> cells&#160;[<xref rid="j_mr-2022-0047_ref_058" ref-type="bibr">58</xref>]. After systemic injection in mice, CD4-targeted mRNA-LNPs accumulated in the spleen and provided a 30-fold higher reporter mRNA signal in splenic T&#160;cells than non-targeted mRNA-LNPs. Intravenous administration of CD4-targeted LNPs loaded with mRNA encoding Cre recombinase led to highly specific loxP-mediated genetic recombination in CD4<sup>+</sup> T&#160;cells (approximately 60% in the spleen and 40% in lymph nodes). CD7 and CD8 have also been used for T&#160;cell targeting due to their high expression levels on T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_059" ref-type="bibr">59</xref>,&#160;<xref rid="j_mr-2022-0047_ref_060" ref-type="bibr">60</xref>].</p></sec><sec id="j_mr-2022-0047_s_004_s_003"><title>Nanoparticles for CAR-T cell engineering</title><p>CAR-T cell therapy has achieved a high response rate in treating hematological malignancies and is an important cellular immunotherapy for treating tumors. Currently, most CAR-T cells are engineered by transduction of T&#160;cells collected from patients and then infused back into the patients. The high cost and complexity of CAR-T cell manufacture make it difficult to achieve worldwide application. To date, FDA-approved CAR-T cell products are all transfected with CAR by lentivirus, which cannot be used directly <italic toggle="yes">in&#160;vivo</italic>. Nawaz et&#160;al. showed that an adeno-associated viral vector (AAV) carrying the CAR gene generates human CD4-targeting CAR-T cells and reduces human T&#160;cell leukemia in a humanized mouse model&#160;[<xref rid="j_mr-2022-0047_ref_061" ref-type="bibr">61</xref>]. However, the AAV vector can be taken up by non-T cells <italic toggle="yes">in&#160;vivo</italic>, resulting in non-targeted toxicity. Therefore, there is a need for <italic toggle="yes">in&#160;vivo</italic> CAR-T-cell production methods that can target T&#160;cells more efficiently.</p><p>Nanoparticles are widely used for nucleic acid delivery and can be used for cell targeting by surface-modified antibodies. Smith et&#160;al. developed in-situ engineered CAR-T cells using polymeric nanoparticles&#160;[<xref rid="j_mr-2022-0047_ref_062" ref-type="bibr">62</xref>]. Anti-CD3e F(ab&#8217;)<sub>2</sub>-modified nanoparticles encapsulating plasmids encoding murine anti-CD19 CAR and hyperactive transposase selectively deliver CAR genes into T&#160;cells <italic toggle="yes">in&#160;vivo</italic>, resulting in long-term disease remission (<xref rid="j_mr-2022-0047_fig_002" ref-type="fig">Figure&#160;2A</xref>). The same strategy could be used for CAR mRNA delivery ex <italic toggle="yes">vivo</italic> and <italic toggle="yes">in&#160;vivo</italic> (<xref rid="j_mr-2022-0047_fig_002" ref-type="fig">Figure&#160;2B</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_063" ref-type="bibr">63</xref>,&#160;<xref rid="j_mr-2022-0047_ref_064" ref-type="bibr">64</xref>]. Compared to plasmid DNA, therapeutic mRNA is pharmacologically and immunologically suited for clinical application. Lipid nanoparticle (LNP)-based mRNA delivery systems have emerged as a potential method for T&#160;cell engineering. LNP-mRNA technology has been successfully used in developing COVID-19 vaccines and has demonstrated potential for treating other diseases&#160;[<xref rid="j_mr-2022-0047_ref_065" ref-type="bibr">65</xref>], [<xref rid="j_mr-2022-0047_ref_066" ref-type="bibr">66</xref>], [<xref rid="j_mr-2022-0047_ref_067" ref-type="bibr">67</xref>]. Billingsley et&#160;al. designed ionizable LNP for mRNA delivery to human T&#160;cells <italic toggle="yes">ex vivo</italic>&#160;[<xref rid="j_mr-2022-0047_ref_068" ref-type="bibr">68</xref>]. A library of 24 ionizable lipids was formulated into LNPs and screened for reporter gene mRNA delivery into human Jurkat cells. The delivery efficiency of the best-performing LNP formulation is greater than the efficiency of lipofectamine and equivalent to electroporation but with low cytotoxicity. CAR-T cells were reprogrammed <italic toggle="yes">in&#160;vivo</italic> by CD5-targeting LNP-carrying CAR mRNA&#160;[<xref rid="j_mr-2022-0047_ref_069" ref-type="bibr">69</xref>]. In a mouse model of heart failure, fibroblast activation protein (FAP)-targeting CAR mRNA was encapsulated in anti-CD5 antibody-functionalized LNP and then delivered into T&#160;cells to generate CAR-T cells against FAP (<xref rid="j_mr-2022-0047_fig_002" ref-type="fig">Figure&#160;2C</xref>). This study also indicated that <italic toggle="yes">in&#160;vivo</italic> generation of CAR-T cells can be a therapeutic platform for cancer and other diseases.</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_002" orientation="portrait"><label>Figure&#160;2:</label><caption><p>Nanoparticles for CAR-T cell engineering. (A) Poly (&#946;-amino ester) (PBAE) nanoparticles functionalized with anti-CD3e F(ab&#8217;)<sub>2</sub> to deliver plasmid DNA for CAR-T cell generation <italic toggle="yes">in&#160;vivo</italic> [<xref rid="j_mr-2022-0047_ref_062" ref-type="bibr">62</xref>]. (B) Anti-CD8 antibody-modified PBAE nanoparticles to deliver mRNA for specific TCR-T or CAR-T cell generation <italic toggle="yes">in&#160;vivo</italic> [<xref rid="j_mr-2022-0047_ref_064" ref-type="bibr">64</xref>]. (C) CD5-targeted LNPs delivering mRNA to FAP for CAR-T cell generation <italic toggle="yes">in&#160;vivo</italic> [<xref rid="j_mr-2022-0047_ref_069" ref-type="bibr">69</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_002.jpg"/></fig></sec><sec id="j_mr-2022-0047_s_004_s_004"><title>Nano-bispecific-engager for enhancing T&#160;cell function</title><p>T cell-mediated killing requires recognizing antigens on the surface of target cells by T&#160;cell surface receptors&#160;[<xref rid="j_mr-2022-0047_ref_070" ref-type="bibr">70</xref>]. However, expression of MHC-I/antigen complex and other tumor cell markers are reduced, resulting in weak interaction between T&#160;cells and tumor cells&#160;[<xref rid="j_mr-2022-0047_ref_071" ref-type="bibr">71</xref>]. Bispecific engagers to enhance recognition between T&#160;cells and tumor cells provide a feasible strategy to solve the problem. Nanoparticles are suitable for bispecific engager design due to their flexible, controllable surface modification and long-circulating time&#160;[<xref rid="j_mr-2022-0047_ref_072" ref-type="bibr">72</xref>,&#160;<xref rid="j_mr-2022-0047_ref_073" ref-type="bibr">73</xref>].</p><p>Cheng et&#160;al. developed synthetic multivalent antibodies retargeted exosomes (SMART-Exos) by displaying two different types of antibodies on the exosomal surface&#160;[<xref rid="j_mr-2022-0047_ref_074" ref-type="bibr">74</xref>]. To enhance immunotherapy in breast tumors, Expi293F&#160;cells were transfected to express epidermal growth factor receptor (EGFR, cancer cell targeting) and anti-CD3 antibody (T&#160;cell targeting), derived single-chain variable fragment (scFv) fusion constructs on the cell surface, then exosomes from these cells were collected (<xref rid="j_mr-2022-0047_fig_003" ref-type="fig">Figure&#160;3A</xref>). The SMART-Exos induced cross-linking of T&#160;cells and EGFR-expressing breast cancer cells, resulting in potent antitumor immunity both <italic toggle="yes">in&#160;vitro</italic> and <italic toggle="yes">in&#160;vivo</italic>. Kosmides et&#160;al. described &#8220;immunoswitch&#8221; iron-dextran nanoparticles coated with two distinct antibodies to block the inhibitory checkpoint PD-L1 pathway and stimulate T&#160;cells through 4-1BB costimulatory signaling&#160;[<xref rid="j_mr-2022-0047_ref_075" ref-type="bibr">75</xref>]. The antibodies to block PD-L1 and stimulate 4-1BB were also used to dual-target tumor cells and T&#160;cells (<xref rid="j_mr-2022-0047_fig_003" ref-type="fig">Figure&#160;3B</xref>). The &#8220;immunoswitch&#8221; nanoparticles demonstrated tumor growth inhibition and prolonged survival in multiple tumor models, including melanoma and colon tumors. Jiang et&#160;al. established a versatile antibody immobilization nanoparticle called immunomodulating nano-adaptors (imNAs) to enhance T&#160;cell-, natural killer cell-, and macrophage-mediated antitumor immune responses&#160;[<xref rid="j_mr-2022-0047_ref_076" ref-type="bibr">76</xref>]. In this strategy, two types of antibodies were immobilized onto single nanoparticles functionalized with anti-Fc antibodies, one for binding T&#160;cells (or other immune cells) and the other for tumor cell targeting (<xref rid="j_mr-2022-0047_fig_003" ref-type="fig">Figure&#160;3C</xref>). Jiang et&#160;al. selected the immune checkpoint inhibitors anti-PD1 antibody and anti-PD-L1 antibody to construct imNAs to enhance T cell-mediated antitumor immunity.</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_003" orientation="portrait"><label>Figure&#160;3:</label><caption><p>Nano-bispecific-engager for enhancing T&#160;cell function. (A) Design and generation of anti-CD3/anti-EGFR synthetic multivalent antibodies retargeted exosomes (SMART-Exos) [<xref rid="j_mr-2022-0047_ref_074" ref-type="bibr">74</xref>]. (B) Immunoswitch particles link PD-L1 checkpoint blockade with 4-1BB costimulation [<xref rid="j_mr-2022-0047_ref_075" ref-type="bibr">75</xref>]. (C) Nano-adaptors promote T cell-mediated cancer therapy [<xref rid="j_mr-2022-0047_ref_076" ref-type="bibr">76</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_003.jpg"/></fig></sec></sec><sec id="j_mr-2022-0047_s_005"><title>Nanoparticle-based strategies for macrophage regulation</title><p>As an essential innate immune subgroup for maintaining homeostasis and defending against exogenous pathogens, macrophages were the first phagocytes discovered. Macrophages play a crucial regulatory role in development, disease (including cancer, inflammation, and autoimmune diseases), and tissue regeneration. Macrophages can circulate in the blood or exist in a stable state in tissues (resident macrophages).</p><p>Macrophages express specific proteins dynamically and reversibly, depending on their environment and degree of activation, resulting in different phenotypes. Activated macrophages are occasionally divided into two simple phenotypes, M1 and M2, representing polarized pro-inflammatory or anti-inflammatory phenotypes. In some diseases, however, macrophages can express markers for the cells&#8217; M1 and M2 subtypes to varying degrees, reflecting that they are in an intermediate activation state. Normally, M1 macrophages have pro-inflammatory effects, characterized by the secretion of pro-inflammatory cytokines (such as IFN-1&#946;, IL-12, and TNF-&#945;), reactive nitrogen intermediates, and reactive oxygen species (ROS), which can clear pathogens and stimulate angiogenesis. In addition, excessive production of pro-inflammatory cytokines by M1 macrophages may cause damage to normal tissue.</p><p>In contrast, M2 macrophages have anti-inflammatory effects, characterized by increased secretion of anti-inflammatory cytokines (including IL-4, IL-10, and IL-13), which promote tissue remodeling and healing, extracellular matrix (ECM) deposition, etc. Excessive M2 behavior promotes tissue fibrosis. The balance of pro-inflammatory and anti-inflammatory responses is often key to the outcome of inflammatory diseases. For example, TAMs, M2 phenotype can promote tumor cell proliferation and metastasis. They promote angiogenesis via vascular endothelial growth factor (VEGF) signaling and inhibit immune function through PD-L1 and other immune checkpoints. Therefore, the development of tumor immunotherapies targeting TAMs has received much attention. The options are to remove it from the tumor and block its tumor-promoting function or restore its immune activation and tumor cytotoxicity functions.</p><p>Strategies for regulating macrophage function include (1) regulating the number of macrophages at the disease site and (2) local or systemic delivery of bioactive molecules to polarize macrophages. The macrophage-targeting accuracy of these immunomodulatory strategies can be optimized by exploiting the properties of the nano-delivery system.</p><sec id="j_mr-2022-0047_s_005_s_001"><title>Nanoparticles for regulating the number of macrophages</title><p>By targeting chemokines and receptors (such as colony-stimulating factor-1 (CSF-1)/CSF-1 receptor (CSF1R), C-C motif chemokine ligand 2 (CCL2)/C-C chemokine receptor 2(CCR2), VEGF/VEGFR), the aggregation of macrophages at the disease site can be controlled. For example, CCL2 is a potent chemokine and an essential mediator in the recruitment of myeloid cells. Majumdar et&#160;al. used nanoparticle-facilitated silencing of CCR2 to reduce the number of inflammatory (Ly6C<sup>hi</sup>) mononuclear cells and improved the healing of myocardial infarction in apolipoprotein E-deficient (apoE<sup>&#8722;/&#8722;</sup>) mice&#160;[<xref rid="j_mr-2022-0047_ref_077" ref-type="bibr">77</xref>]. Macrophage cell membranes are generally negatively charged. Positively charged (cationic) particles are more likely to trigger inflammatory responses than negatively charged (anion) and neutral particles. Shen et&#160;al. used cationic nanoparticles to deliver CCR2 siRNA&#160;[<xref rid="j_mr-2022-0047_ref_078" ref-type="bibr">78</xref>]. This delivery strategy effectively inhibits the recruitment of monocytes in the peripheral blood, bone marrow, and spleen and reduces TAM invasion in the tumor, thus reversing the immunosuppressive tumor microenvironment (<xref rid="j_mr-2022-0047_fig_004" ref-type="fig">Figure&#160;4A</xref>).</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_004" orientation="portrait"><label>Figure&#160;4:</label><caption><p>Nanoparticle-based strategies for macrophage regulation. (A) CNP/siCCR2-mediated tumor microenvironment modification and cancer therapy [<xref rid="j_mr-2022-0047_ref_078" ref-type="bibr">78</xref>]. (B) Design of the M2NP for M2-like TAM-specific molecular-targeted immunotherapy [<xref rid="j_mr-2022-0047_ref_079" ref-type="bibr">79</xref>]. (C) Tumor pH triggered release of BLZ-945 and Pt-prodrug conjugated small particles for spatial delivery to TAMs and tumor cells [<xref rid="j_mr-2022-0047_ref_080" ref-type="bibr">80</xref>]. (D) Nanoparticle-based strategy to deliver RNAi for VEGF silencing in both TAMs and lung cancer cells [<xref rid="j_mr-2022-0047_ref_082" ref-type="bibr">81</xref>], (E) S-BsNA improves the antitumor response of macrophage [<xref rid="j_mr-2022-0047_ref_088" ref-type="bibr">82</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_004.jpg"/></fig><p>Furthermore, since the small molecule drug does not target TAMs, modifying macrophage-associated ligands on the nanoparticle&#8217;s surface can improve the specificity of targeting macrophages. Conde et&#160;al. designed potent and selective biohybrid RNA interference&#8211;M2 peptide nanoparticles to induce specific and long-lasting gene therapy in inflammatory TAMs. Qian et&#160;al. developed double-targeted nanoparticles modified with &#945;-peptide (SR-B1 targeting peptide) and M2pep (M2 macrophage binding peptide), when loaded with anti-colony-stimulating factor 1 receptor (anti-CSF-1R) siRNA, it can specifically block the survival signals of M2-like TAMs and clear them from melanoma (<xref rid="j_mr-2022-0047_fig_004" ref-type="fig">Figure&#160;4B</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_079" ref-type="bibr">79</xref>]. This strategy can inhibit tumor growth and prolong survival. Such systems reduce TAM infiltration at disease sites by inhibiting macrophage recruitment. Drugs can also be specifically delivered to TAMs via environmentally responsive nanoparticle release. Shen et&#160;al. designed acid-responsive clusters of nanoparticles (SCNs) loaded with BLZ-945 (a small molecule inhibitor of CSF-1) and platinum (IV) prodrugs (<xref rid="j_mr-2022-0047_fig_004" ref-type="fig">Figure&#160;4C</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_080" ref-type="bibr">80</xref>], and Wang et&#160;al. designed light-sensitive BLZ@S-NP/Pt to achieve accurate delivery of BLZ-945 to TAMs and eliminate them&#160;[<xref rid="j_mr-2022-0047_ref_081" ref-type="bibr">83</xref>]. Conde et&#160;al. present highly potent and selective biohybrid RNA interference (RNAi)-peptide nanoparticles (NPs) to induce specific and long-lasting gene therapy for regulating inflammatory TAMs (<xref rid="j_mr-2022-0047_fig_004" ref-type="fig">Figure&#160;4D</xref>), which can reduce the recruitment of inflammatory TAMs in lung tumor tissue, reduces tumor size (about 95%), and increases animal survival (about 75%) in mice&#160;[<xref rid="j_mr-2022-0047_ref_082" ref-type="bibr">81</xref>].</p></sec><sec id="j_mr-2022-0047_s_005_s_002"><title>Nanoparticles for reprogramming macrophage phenotype</title><p>Regulating macrophage phenotypes may be more important than regulating the overall number of macrophages at the disease site. Small molecule inhibitors, cytokines, CpG oligonucleotides, and Toll-Like-Receptor (TLR) agonists can be used to reprogram TAMs. Polylysine, polyethylenimine (PEI), cationic gelatin, and glucan can activate M1 macrophages through the toll-like receptor pathway and specifically induce IL-12 secretion. Strong stimulation of the Th1 response results in the reversal of the M1 phenotype from M2 TAMs. Li et&#160;al. synthesized porous hollow iron oxide nanoparticles (PHNPs) loaded with P13&#160;K&#947; small molecule inhibitors (3-MA) and targeted TAMs by adding a mannitol modification. PHNPs combined with 3-MA was used for macrophage-activating inflammatory factor NF-&#954;B p65&#160;[<xref rid="j_mr-2022-0047_ref_083" ref-type="bibr">84</xref>]. The synergistic conversion of TAMs into pro-inflammatory M1 macrophages activates the immune response and inhibits tumor growth <italic toggle="yes">in&#160;vivo</italic>. Huang et&#160;al. designed a pH-sensitive galactose-modified polymer nanoparticle to co-deliver CpG oligonucleotides and anti-IL-10 antibodies to repolarize M2 TAMs into M1 macrophages. CpG oligonucleotides enhance secretion of the tumor suppressor IL-12, and anti-IL-10 antibodies inhibit the IL-10 signaling axis, reversing the polarization of the anti-inflammatory TAMs. Notably, Awojoodu et&#160;al. found that the release of S1P3 receptor agonist FTY720 in&#160;PLGA scaffold in mice at the site of ischemic muscle injury preferred the local mobilization of monocyte subpopulations that were polarized into M2-like macrophages (as measured by CD206 expression), leading to increased arteriogenesis&#160;[<xref rid="j_mr-2022-0047_ref_084" ref-type="bibr">85</xref>]. ROS are critical regulators of macrophage polarization and activation. Iron oxide- or photosensitizer-bearing nanoparticles can produce ROS and repolarize TAMs into M1 macrophages. Zanganeh et&#160;al. demonstrated that ROS from the Fenton reaction mediated by FDA-approved glucan-coated iron oxide nanoparticles (Ferumoxytol) inhibited breast cancer progression and lung and liver metastasis by inducing the repolarization of TAMs into M1 macrophages.</p><p>Nanoparticles can also be functionalized to serve as contrast agents in imaging modalities, enabling a dual-functional or diagnostic approach. For example, Harel-Adar et&#160;al. designed liposomes loaded with iron oxide and decorated with phosphatidylserine (PS). This apoptotic cell surface ligand triggers macrophage uptake and subsequent phenotypic transformation to an M2-like phenotype, enabling manipulation of macrophage phenotypes and imaging and tracking via magnetic resonance imaging&#160;[<xref rid="j_mr-2022-0047_ref_085" ref-type="bibr">86</xref>].</p><p>The interaction between CD47 and SIRP-&#945; inhibits phagocytosis of red blood cells and other normal cells. However, CD47 also protects cancer cells from phagocytosis, and excess expression of CD47 has been associated with poor prognosis in various solid tumors. Blocking the CD47/SIRP-&#945; pathway is expected to restore the antitumor efficacy of TAMs and promote phagocytosis of tumor cells, which may also trigger macrophage repolarization. Chen et&#160;al. developed core&#8211;shell albumin nanoparticles loaded with anti-CD47 and anti-PD1 (aPD1@&#945;CD47 complex)&#160;[<xref rid="j_mr-2022-0047_ref_086" ref-type="bibr">87</xref>]. The nanoparticles first released &#945;CD47 from the particle surface to block the tumor&#8217;s &#8220;don&#8217;t eat me&#8221; signal and then released aPD1 from the nuclear layer to increase lymphocyte infiltration of the tumor. The group also developed in-situ fibrin gels containing calcium carbonate nanoparticles loaded with anti-CD47 antibodies that repolarize TAMs into&#160;M1 macrophages and promote phagocytosis. Kulkarni et&#160;al. developed a supramolecular assembly consisting of amphiphilic molecules that inhibit colony-stimulating factor 1 receptor (CSF-1R) and contain SiRP-&#945;-blocking antibodies&#160;[<xref rid="j_mr-2022-0047_ref_087" ref-type="bibr">88</xref>]. This assembly enhances M2-M1 repolarization in the tumor microenvironment and significantly improves antitumor and anti-metastatic efficacy. Chen et&#160;al. describe dual-functional super bispecific nano-antibodies (S-BsNA) (<xref rid="j_mr-2022-0047_fig_004" ref-type="fig">Figure&#160;4E</xref>) constructed by immobilizing two types of traditional monoclonal antibodies (&#945;CSF1R and &#945;CD47) onto a universal antibody-immobilization platform. The S-BsNA simultaneously reprogram the phenotype of TAMs&#160;and establish a close physical connection between effector cells and tumor cells, which can efficiently augment innate antitumor immunity both <italic toggle="yes">in&#160;vitro</italic> and <italic toggle="yes">in&#160;vivo</italic>&#160;[<xref rid="j_mr-2022-0047_ref_088" ref-type="bibr">82</xref>]<italic toggle="yes">.</italic>
</p></sec><sec id="j_mr-2022-0047_s_005_s_003"><title>Engineering macrophage for drug delivery</title><p>Macrophage-based drug carriers are also versatile. They circulate in the blood like red blood cells and neutrophils and specifically target tumor tissues by binding to the vascular cell adhesion molecule-1 (VCAM-1) via &#945;4 and &#946;1 integrins of macrophages. As a result, researchers are trying to use macrophages, macrophage-derived exosomes, or nanoparticles coated with macrophage cell membranes as drug-delivery vehicles to target and kill tumor cells. Guo et&#160;al. found that DOX-loaded M1-type macrophages inhibit tumor invasion and can transfer drugs to ovarian cancer cells via tunneling nanotubes. The liposome dox has no such effect&#160;[<xref rid="j_mr-2022-0047_ref_089" ref-type="bibr">89</xref>]. Choi et&#160;al. developed peritoneal macrophages loaded with DOX-liposome (macrophages extracted from the inflamed intestinal abdominal cavity), which had&#160;a stronger inhibitory effect on tumor metastasis than DOX-liposome&#160;[<xref rid="j_mr-2022-0047_ref_090" ref-type="bibr">90</xref>]. Macrophages can be further modified to enhance the targeting of these vectors or endow them with multiple functions. Cao et&#160;al. developed a transferable legume protein-reacting macrophage LD-MDS. In the tumor microenvironment, LD-MDS treated with legume protease can be transformed into exosome-like nanovesicles loaded with solanine (DM4), which is then internalized by metastatic 4T1 cancer cells and inhibits metastasis&#160;[<xref rid="j_mr-2022-0047_ref_091" ref-type="bibr">91</xref>]. Macrophage-derived exosomes have surface membrane properties like those of macrophages. Therefore, M1-macrophage-derived exosomes (M1-exos) can be used to deliver various anticancer drugs for tumor therapy. Nie et&#160;al. used click chemistry to modify M1-exos with anti-CD47 and anti-SiRP-&#945; antibodies via pH-sensitive linkers&#160;[<xref rid="j_mr-2022-0047_ref_092" ref-type="bibr">92</xref>]. They demonstrated that M1-exo blocks CD47 and SiRP-&#945; and transforms M2-type macrophages into M1-type macrophages, thereby enhancing tumor cell removal by phagocytosis.</p><p>Modulating TAMs alone is commonly not sufficient to inhibit disease progression completely and needs to combined with other treatment options such as immunotherapy or chemotherapy. In addition, nanoparticle design is vital in the use of engineered macrophages (CAR macrophages, etc.) for cancer immunotherapy. The size, shape, targeting, and drug-delivery behavior of nanocarriers must be carefully considered.</p></sec></sec><sec id="j_mr-2022-0047_s_006"><title>Nanoparticle-based strategies for DC regulation</title><p>DCs are the most efficient, potent, professional APCs. They are derived from the hematopoietic stem cells of the bone marrow, and play a vital role in modulating lymphocyte and inflammation&#160;[<xref rid="j_mr-2022-0047_ref_093" ref-type="bibr">93</xref>]. DCs located in lymphoid organs are ideal for inducing T&#160;cell priming and amplification, since these DCs are close to T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_094" ref-type="bibr">94</xref>]. Besides activation, DCs also induce tolerance to self-antigens to avoid autoimmune reactions. Thus, DCs provide a connection between innate and adaptive immunity&#160;[<xref rid="j_mr-2022-0047_ref_095" ref-type="bibr">95</xref>]. The potential of DCs as immunotherapy targets has been addressed in clinical studies, particularly as a target for vaccination&#160;[<xref rid="j_mr-2022-0047_ref_096" ref-type="bibr">96</xref>]. The delivery of these drugs to DCs remains a challenge. Nanoparticles can be designed to encapsulate drugs and interfere with DC function, even as vaccine adjuvants, making this a promising strategy for pathogenic infection, cancer, and immune disease therapy. For instance, our group created a DC-targeting cancer vaccine&#160;[<xref rid="j_mr-2022-0047_ref_097" ref-type="bibr">97</xref>], as well as two types of nanomedicine-delivered nucleic acids and peptides to ameliorate autoimmune diseases and induce transplant tolerance&#160;[<xref rid="j_mr-2022-0047_ref_098" ref-type="bibr">98</xref>,&#160;<xref rid="j_mr-2022-0047_ref_099" ref-type="bibr">99</xref>].</p><p>Whether to activate the immune system or induce tolerance, DC-targeting nanoparticles are mainly used as vaccines to modulate DC function to achieve disease prevention and treatment. Here we describe the application of nanoparticles to induce immune activation and immune tolerance, focusing on research progress with nanotechnology to prepare DC-targeting vaccines, and summarize various models, including their mechanism of action, therapeutic strategies and results, and future prospects.</p><sec id="j_mr-2022-0047_s_006_s_001"><title>DC-targeting peptide/protein nanoparticles</title><p>DC-targeting vaccines can induce both cellular and humoral immune responses. In recent years, different strategies have been explored for efficient vaccine development&#160;[<xref rid="j_mr-2022-0047_ref_100" ref-type="bibr">100</xref>]. Nanoparticle-based peptide or protein-delivery provides a flexible and effective platform for vaccine development by coating the particles with antigens via various methods. The primary methods for antigen presentation on nanoparticles are chemical conjugation, genetic fusion, and tag coupling. Shimp et&#160;al. reported that recombinant Pfs25H conjugated to&#160;a <italic toggle="yes">Pseudomonas aeruginosa</italic> exoprotein A (EPA) was able to&#160;overcome the poor immunogenicity of Pfs25H&#160;[<xref rid="j_mr-2022-0047_ref_101" ref-type="bibr">101</xref>]. Pfs25-EPA provided a 75&#8211;110-fold increase in specific antibody generation compared to Psf25 alone and was used in a phase 1 human trial. The antigen was lysine-treated, and then conjugated to the cysteine of EPA&#160;[<xref rid="j_mr-2022-0047_ref_102" ref-type="bibr">102</xref>]. Another common example is virus-like-particles (VLPs), which are virus capsid protein platforms with which stable nanoparticles are built&#160;[<xref rid="j_mr-2022-0047_ref_103" ref-type="bibr">103</xref>]. We discuss applications of VLP vaccines later. Tag coupling typically involves binding of two proteins that are engineering with a tag or partner protein, such as the&#160;popular biotin-avidin, Halo Tag, and SpyTag/SpyCatcher&#160;[<xref rid="j_mr-2022-0047_ref_104" ref-type="bibr">104</xref>]. Biotin-Avidin is one of the strongest non-covalent interactions known and enhances antibody production&#160;[<xref rid="j_mr-2022-0047_ref_105" ref-type="bibr">105</xref>]. Decorating the surface of DCs with nanotechnology is also a promising strategy for vaccine development. Irvine et&#160;al. designed a series of amphiphile ligands (amph-ligands) carrying peptides that bind albumin after injection, are trafficked to lymph nodes, and inserted into the DC membrane to prime CAR-T cells (<xref rid="j_mr-2022-0047_fig_005" ref-type="fig">Figure&#160;5A</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_106" ref-type="bibr">106</xref>].</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_005" orientation="portrait"><label>Figure&#160;5:</label><caption><p>Nanoparticles for targeting DCs. (A) DC-targeting peptide-amph-ligand vaccine to boost CAR-T cells [<xref rid="j_mr-2022-0047_ref_106" ref-type="bibr">106</xref>]. (B) The scheme of CLAN<sub>mRNA</sub> vaccines induce anti-tumor immune response [<xref rid="j_mr-2022-0047_ref_097" ref-type="bibr">97</xref>]. (C) The scheme of bioreducible nanogels for vaccination [<xref rid="j_mr-2022-0047_ref_112" ref-type="bibr">107</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_005.jpg"/></fig><p>Proteins can also self-assemble into nanoparticles or be conjugated to other molecules. Irvine et&#160;al. developed two vaccines with heavily glycosylated human immunodeficiency virus (HIV) antigens that are shuttled to DCs in germinal centers via complement, mannose-binding lectin (MBL), and immunogen glycan, all of which were more effective than monomeric antigens. Follicular DC targeting was lost in MBL-deficient mice or after immunogen deglycosylation&#160;[<xref rid="j_mr-2022-0047_ref_107" ref-type="bibr">108</xref>,&#160;<xref rid="j_mr-2022-0047_ref_108" ref-type="bibr">109</xref>]. In a subsequent study, they developed pharmacokinetically tuned, high-potency antitumor vaccines by fusing the peptide epitopes to albumin&#160;[<xref rid="j_mr-2022-0047_ref_109" ref-type="bibr">110</xref>]. The new formulations of these vaccines exhibited more efficient antigen uptake, reduced proteolytic degradation, less antigen presentation in uninflamed distal lymphoid organs, and increased vaccine immunogenicity. Dye-binding endogenous albumin can be used to identify sentinel lymph nodes in cancer patients&#160;[<xref rid="j_mr-2022-0047_ref_110" ref-type="bibr">111</xref>]. Given that albumin-bound compounds can avoid elimination by phagocytes and travel to lymph nodes by &#8220;albumin hitchhiking&#8221;, Irvine et&#160;al. developed safe and potent molecular vaccines by synthesizing amphiphiles (amph-vaccines) composed of the antigens or adjuvants and lipophilic albumin-binding tails&#160;[<xref rid="j_mr-2022-0047_ref_111" ref-type="bibr">112</xref>]. Immunization of mice with these optimized CpG-DNA/peptide amph-vaccines resulted in marked vaccine accumulation in lymph nodes accompanied by high levels of T&#160;cell priming and enhanced antitumor efficacy.</p></sec><sec id="j_mr-2022-0047_s_006_s_002"><title>DC targeting with polymeric nanoparticles</title><p>Polymeric nanoparticles have been exploited in vaccine development due to their biocompatibility, biodegradability, and reduced cytotoxicity. Polymer-based nanoparticles can protect nucleic acids from extracellular ribonucleases and mediate efficient antigen uptake and expression by DCs. Antigens can be encoded as RNA, so nanoparticle delivery of RNA targeting DCs can be used as a vaccine system&#160;[<xref rid="j_mr-2022-0047_ref_113" ref-type="bibr">113</xref>]. Fan et&#160;al. used cationic lipid-assisted PEG-b-PLGA nanoparticles encapsulating mRNA to create a cancer vaccine&#160;[<xref rid="j_mr-2022-0047_ref_097" ref-type="bibr">97</xref>]. They demonstrated that nanoparticles loaded with OVA mRNA enter and stimulate the maturation of DCs, promoting activation of OVA-specific T&#160;cells (<xref rid="j_mr-2022-0047_fig_005" ref-type="fig">Figure&#160;5B</xref>). In an effort to&#160;reprogram DCs to induce strong antitumor immunity, they created a co-delivery immunotherapeutic strategy by encapsulating siRNA targeting phagocytosis checkpoint signal regulatory protein &#945; (SIRP&#945;) and stimulator of interferon genes (STING) (NP<sub>siSIRP&#945;/cGAMP</sub>) to induce DCs to&#160;actively capture tumor antigens and produce type I interferons (IFNs). Intravenous injection of NP<sub>siSIRP&#945;/cGAMP</sub> activated DCs and T&#160;cells to eradicate tumors&#160;[<xref rid="j_mr-2022-0047_ref_114" ref-type="bibr">114</xref>].</p><p>PLGA nanoparticles have also been used to deliver hepatitis-B virus antigen&#160;[<xref rid="j_mr-2022-0047_ref_115" ref-type="bibr">115</xref>], tetanus toxoid&#160;[<xref rid="j_mr-2022-0047_ref_116" ref-type="bibr">116</xref>], hydrophobic antigen&#160;[<xref rid="j_mr-2022-0047_ref_117" ref-type="bibr">117</xref>], and other antigens using PLA, PCL, and other copolymers as vaccine carriers. Kanchan et&#160;al. reported that immunization with PLA particles loaded with antigen and alum generated a memory antibody response&#160;[<xref rid="j_mr-2022-0047_ref_118" ref-type="bibr">118</xref>]. With a single immunization, a PLA nanoparticle-based vaccine entrapping tetanus or diphtheria toxin induced high levels of memory antibody compared to soluble antigen. Continuous and slow-release of antigen from nanoparticles are important features of a single immunization-induced memory antibody response. PCL-based nanoparticles have been tested for vaccine delivery of <italic toggle="yes">Schistosoma mansoni</italic> antigen&#160;[<xref rid="j_mr-2022-0047_ref_119" ref-type="bibr">119</xref>]. Natural polymers are also used as adjuvants in vaccine. Li et&#160;al. developed a bioreducible alginate-PEI nanogel for antigen delivery and found that it exhibited great antigen-loading capacity without causing cytotoxicity (<xref rid="j_mr-2022-0047_fig_005" ref-type="fig">Figure&#160;5C</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_112" ref-type="bibr">107</xref>].</p></sec><sec id="j_mr-2022-0047_s_006_s_003"><title>DC targeting with inorganic nanoparticles</title><p>Inorganic nanoparticles such carbon, gold, and silica have been used for vaccine studies. Wang et&#160;al. reported a novel carbon nanoparticle adjuvant for oral vaccines&#160;[<xref rid="j_mr-2022-0047_ref_120" ref-type="bibr">120</xref>]. Their optimized 470-nm carbon nanoparticle contained large mesopores and macropores for antigen loading. After oral immunization with the BSA-loaded carbon nanoparticle, the IgG titer reached levels commensurate to conventional immunization using Freund&#8217;s complete adjuvant through parenteral administration. Xu et&#160;al. developed gold nanorods engineered with cetyltrimethylammonium bromide (CTAB), poly (diallydimethylammonium chloride) (PDDAC), and polyethyleneimine (PEI) carrying plasmid as a DNA vaccine for HIV-1&#160;[<xref rid="j_mr-2022-0047_ref_121" ref-type="bibr">121</xref>]. Their plasmid-loaded gold nanorods activated APCs, resulting in significant T&#160;cell proliferation. Interestingly, different surface modifications induced variable immune activation. Tao et&#160;al. also used gold nanoparticles with M2 membrane protein to induce a strong antibody response to influenza A&#160;[<xref rid="j_mr-2022-0047_ref_122" ref-type="bibr">122</xref>]. Silica-based nanoparticles are convenient for surface functionalization and vaccine delivery. An et&#160;al. developed a toll-like receptor 9 (TLR-9) agonist and antigen loaded, amine modified silica nanoparticle as tumor vaccine&#160;[<xref rid="j_mr-2022-0047_ref_123" ref-type="bibr">123</xref>]. These silica nanoparticles accumulated in draining lymph nodes, and delivered antigen to APCs. More importantly, surface-modified silica nanoparticles reduced the systemic toxicity of TLR-9 and provided an effective vaccine platform.</p></sec><sec id="j_mr-2022-0047_s_006_s_004"><title>DC targeting by lipid nanoparticles</title><p>In recent years, lipid nanoparticles (LNPs) have seen exciting development as part of the COVID-19 mRNA vaccine initiative. LNPs protect and transport mRNA, can be used to transport hydrophobic or hydrophilic molecules, and are suitable for antigen delivery. Moon et&#160;al. reported using antigen-loaded multilamellar lipid nanoparticles as vaccines to induce T and B&#160;cell responses&#160;[<xref rid="j_mr-2022-0047_ref_124" ref-type="bibr">124</xref>]. The interbilayer-crosslinked multilamellar lipid vesicles entrapped protein antigens in the vesicle, and adjuvant in the vesicle wall. Ichihashi et&#160;al. reported phosphatidylserine (PS)-liposomes as vaccines&#160;[<xref rid="j_mr-2022-0047_ref_125" ref-type="bibr">125</xref>]. Antigens conjugated to PS-liposomes were effectively taken up by APCs and induced an antigen-specific CD8<sup>+</sup> T&#160;cell response and a T helper cell-mediated immune response. Sahin et&#160;al. developed RNA-lipoplexes (RNA-LPX) to deliver vaccine antigens to DCs&#160;[<xref rid="j_mr-2022-0047_ref_126" ref-type="bibr">126</xref>]. They developed a strategy for precisely and effectively targeting DCs <italic toggle="yes">in&#160;vivo</italic> by preparing lipid carries with an optimized net charge, without modifying particles with molecular ligands. The RNA-LPX led to the release of interferon-&#945; (IFN&#945;) by plasmacytoid DCs (pDCs) and the activation of inflammatory immune mechanisms in the early systemic phase of viral infection. Intravenous injection of RNA-LPX induced strong effector and memory T&#160;cell responses and triggered potent IFN&#945;-dependent rejection of progressive tumors. They provided a universal vaccine strategy for systemic targeting of DCs and induction of adaptive as well as type-I-IFN-mediated innate immune responses for cancer immunotherapy. T&#252;reci et&#160;al. developed individualized mutanome vaccines by implementing an RNA-based poly-neo-epitope against a spectrum of cancer mutations to solve the inefficient spontaneous immune recognition of mutations. This concept was applied in patients with melanoma and the results showed that individual mutations can be exploited as personalized immunotherapy in this patient population&#160;[<xref rid="j_mr-2022-0047_ref_127" ref-type="bibr">127</xref>]. DCs also play a vital role in immune tolerance, preventing autoimmune disease&#160;[<xref rid="j_mr-2022-0047_ref_128" ref-type="bibr">128</xref>]. Sahin et&#160;al. designed a safe and efficient method for noninflammatory delivery of mRNA-encoded antigens to control autoreactive T&#160;cells without disturbing normal immune reactions to treat autoimmune diseases. Systemic delivery of nanoparticle-formulated one methylpseudouridine-modified messenger RNA (m1&#936; mRNA) coding for disease-related autoantigens promotes antigen presentation on DCs in the spleen without costimulatory signals. The vaccines ameliorated disease in several multiple sclerosis mouse models with a reduction of effector T&#160;cells and the development of regulatory T&#160;cells (<xref rid="j_mr-2022-0047_fig_006" ref-type="fig">Figure&#160;6A</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_129" ref-type="bibr">129</xref>,&#160;<xref rid="j_mr-2022-0047_ref_130" ref-type="bibr">130</xref>]. In addition to protein and mRNA, LNPs can also be used to deliver DNA vaccines. Mucker et&#160;al. reported lipid nanoparticles formulated using Andes virus or Zika virus DNA vaccines to promote immune responses in non-rodent laboratory animals&#160;[<xref rid="j_mr-2022-0047_ref_131" ref-type="bibr">131</xref>].</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_006" orientation="portrait"><label>Figure&#160;6:</label><caption><p>Nanotechnology for regulating DCs. (A) The scheme of anti-inflammatory mRNA vaccine to induce tolerance [<xref rid="j_mr-2022-0047_ref_130" ref-type="bibr">130</xref>]. (B) Genetically engineered outer-membrane vesicles (OMVs), and (C) Hybrid membrane vesicles containing bacterial cytoplasmic membrane [<xref rid="j_mr-2022-0047_ref_146" ref-type="bibr">132</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_006.jpg"/></fig></sec><sec id="j_mr-2022-0047_s_006_s_005"><title>VLP nanoparticles for targeting DCs</title><p>VLPs are virus-mimic but are not infectious. VLPs are composed of several proteins, including viral capsids, cores or envelopes&#160;[<xref rid="j_mr-2022-0047_ref_132" ref-type="bibr">133</xref>]. VLPs are effective vaccines because of their size and structural similarity to natural viruses&#160;[<xref rid="j_mr-2022-0047_ref_133" ref-type="bibr">134</xref>]. VLPs also provide a platform to display additional fused proteins. Lusso et&#160;al. developed a VLP with a membrane-anchored HIV-1 envelope (Env) and SIV Gag proteins to prevent HIV infection. Immunization with these mRNA-carrying Env-Gag VLPs induced production of neutralized antibodies and triggered robust CD4<sup>+</sup> T&#160;cell responses. The VLP mRNA platform thus provides a promising strategy for HIV-1 vaccine development&#160;[<xref rid="j_mr-2022-0047_ref_134" ref-type="bibr">135</xref>]. Stephen et&#160;al. designed Tandem-HBc VLPs and expressed them in bacterial, yeast, and plant systems&#160;[<xref rid="j_mr-2022-0047_ref_135" ref-type="bibr">136</xref>]. Chemical techniques can be used for VLP surface modifications. Lysine residues are a common target for conjugation, because free lysine forms stable amide bonds with N-hydroxysuccinimide esters&#160;[<xref rid="j_mr-2022-0047_ref_136" ref-type="bibr">137</xref>]. Stefanetti et&#160;al. developed a glycoconjugate vaccine through click chemistry&#160;[<xref rid="j_mr-2022-0047_ref_137" ref-type="bibr">138</xref>]. Different types of VLPs are classified by their structure. Enveloped VLPs consist of a cell membrane from the host cell and present viral protein on the surface&#160;[<xref rid="j_mr-2022-0047_ref_138" ref-type="bibr">139</xref>]. Yao et&#160;al. produced enveloped VLPs containing SIV Gag protein and HIV Env protein&#160;[<xref rid="j_mr-2022-0047_ref_139" ref-type="bibr">140</xref>]. The enveloped VLPs have been used in vaccines against retroviruses, influenza A, and hepatitis C virus&#160;[<xref rid="j_mr-2022-0047_ref_140" ref-type="bibr">141</xref>]. Compared to lipid nanoparticles or other nanoparticle-based vaccines, enveloped VLPs have a larger size (&gt;100&#160;nm), which will limit their migration to lymph nodes&#160;[<xref rid="j_mr-2022-0047_ref_141" ref-type="bibr">142</xref>]. Non-enveloped VLPs have a simple composition in comparison to enveloped VLPs, as they do not contain host cell membrane and are preferable for vaccines&#160;[<xref rid="j_mr-2022-0047_ref_142" ref-type="bibr">143</xref>]. They are smaller than enveloped VLPs, and easily migrate to lymph nodes&#160;[<xref rid="j_mr-2022-0047_ref_136" ref-type="bibr">137</xref>].</p></sec><sec id="j_mr-2022-0047_s_006_s_006"><title>DC targeting by other nanoparticles</title><p>There are several versatile novel vaccine designs. Moon et&#160;al. developed personalized vaccines for immunotherapy to stimulate strong T&#160;cell responses. They co-delivered high-density lipoprotein-mimicking nanodiscs with antigen peptides and adjuvants to lymphoid organs to promote antigen presentation on DCs. This multi-epitope vaccination triggered broad-spectrum T&#160;cell responses and inhibited tumor growth when combined with immune checkpoint blocking antibodies&#160;[<xref rid="j_mr-2022-0047_ref_143" ref-type="bibr">144</xref>]. Ding et&#160;al. developed a tubular DNA nanodevice vaccine composed of two molecular adjuvants with antigen peptide in the inner cavity to trigger long-term T&#160;cell activation and cancer cytotoxicity&#160;[<xref rid="j_mr-2022-0047_ref_144" ref-type="bibr">145</xref>]. Liu et&#160;al. described a genetically engineered cell membrane nanovesicle that integrates antigen self-presentation and immunosuppression reversal (ASPIRE) for cancer immunotherapy. ASPIRE promotes antigen delivery to lymphoid organs and eliminates tumors by activating both native T&#160;cells and exhausted T&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_145" ref-type="bibr">146</xref>]. Inspired by natural immune defenses against bacterial invasion, Nie et&#160;al. developed cancer vaccines based on bacterial membrane materials, including genetically engineered outer-membrane vesicles (OMVs) and hybrid membrane vesicles containing bacterial cytoplasmic membrane to induce strong tumor regression (<xref rid="j_mr-2022-0047_fig_006" ref-type="fig">Figure&#160;6B&#8211;C</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_146" ref-type="bibr">132</xref>]. Li et&#160;al. developed potent vesicular cancer nanovaccines (BTs) by fusing bacterial OMVs and tumor cell membranes. The bacteria-derived pathogenic adjuvants in BTs can target DCs and confer an excellent tumor prophylactic effect&#160;[<xref rid="j_mr-2022-0047_ref_147" ref-type="bibr">147</xref>].</p><p>DC-targeting nanoparticles can also be used for tracking and imaging. Pham et&#160;al. developed superparamagnetic iron&#160;oxide nanoparticle (SPIOs) for DC tracking without compromising cell function and investigated the migration of SPIO-labeled DCs in a syngeneic mouse model using magnetic resonance imaging. With polylysine, dextran-coated SPIOs can be taken up by DCs within 1&#160;h of incubation, and injection of the SPIO-labeled DCs in the footpad showed migration from the injection site to the corresponding popliteal lymph node. Thus, SPIO-enhanced MR imaging can be used to track DC migration <italic toggle="yes">in&#160;vivo</italic>&#160;[<xref rid="j_mr-2022-0047_ref_148" ref-type="bibr">148</xref>].</p></sec></sec><sec id="j_mr-2022-0047_s_007"><title>Nanoparticle-based strategies for granulocyte regulation</title><p>Granulocytes comprise the largest proportion of white blood cells. They survive a few hours after entering the bloodstream, then leave and die&#160;[<xref rid="j_mr-2022-0047_ref_149" ref-type="bibr">149</xref>]. Granulocytes include eosinophils, neutrophils, and basophils, which are differentiated by granule staining. Neutrophils are most abundant in the peripheral circulation and are the main defense effector cells of antibody and complement-mediated immune responses&#160;[<xref rid="j_mr-2022-0047_ref_150" ref-type="bibr">150</xref>]. They can be rapidly recruited to sites of tissue injury to perform antibacterial and inflammatory functions through phagocytosis, degranulation, release of&#160;neutrophil extracellular traps (NETs) and antigen presentation&#160;[<xref rid="j_mr-2022-0047_ref_151" ref-type="bibr">151</xref>,&#160;<xref rid="j_mr-2022-0047_ref_152" ref-type="bibr">152</xref>].</p><p>Neutrophils participate in the pathogenesis of widespread human diseases and abnormal physiological functions of neutrophils, such as underactivity or overactivation, are likely to develop into disease&#160;[<xref rid="j_mr-2022-0047_ref_153" ref-type="bibr">153</xref>]. Therefore, targeting or intervening with neutrophils and their related pathways in the treatment of inflammatory diseases and cancer is a new therapeutic approach. Nanoparticle-based strategies for neutrophil regulation include <italic toggle="yes">in&#160;vivo</italic> hijacking of neutrophils by multifunctional nanoparticles across the vascular barrier for targeted therapy. The goal is to control disease progression by regulating neutrophil infiltration.</p><sec id="j_mr-2022-0047_s_007_s_001"><title>Nanoparticles for hijacking neutrophils to across the vascular barrier</title><p>Neutrophils release cytotoxic substrates involving ROS and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to mediate the elimination of tumor cells, but also secrete factors that inhibit proliferation. Therefore, if neutrophils can be precisely targeted and manipulated <italic toggle="yes">in&#160;vivo</italic>, they could be used for tumor treatment and theragnostic&#160;[<xref rid="j_mr-2022-0047_ref_154" ref-type="bibr">154</xref>,&#160;<xref rid="j_mr-2022-0047_ref_155" ref-type="bibr">155</xref>]. Li et&#160;al. constructed a nano-pathogen (NPN) mimic by coating nanoparticles with vesicles secreted by bacteria along with homogeneous pathological functions, thus hitchhiking neutrophil circulation&#160;[<xref rid="j_mr-2022-0047_ref_156" ref-type="bibr">156</xref>]. In a mouse model, tumors were completely eradicated by a combined application of PTT and NPNs. In another study, Li et&#160;al. achieved active and precise regulation of the surface protein corona by changing the characteristics of the carrier, enabling hijacking of endogenous neutrophils and delivery of nanomedicine to the lung by taking advantage of the natural delivery of neutrophils for the precise treatment of pneumonia&#160;[<xref rid="j_mr-2022-0047_ref_157" ref-type="bibr">157</xref>].</p><p>Tang et&#160;al. modified 5-HT on nanoparticles loaded with photosensitizer and Zileuton (a leukotriene inhibitor) for targeting MPO and neutrophils in a similar way&#160;[<xref rid="j_mr-2022-0047_ref_154" ref-type="bibr">154</xref>]. Noninvasive positron emission tomography studies confirmed the MPO-targeting properties of 5-HT-modified NPs, then photodynamic therapy was used to launch an inflammatory response, which mediated the accumulation and retention of targeted neutrophils in breast cancer models.</p></sec><sec id="j_mr-2022-0047_s_007_s_002"><title>Nanoparticles for restraining neutrophil infiltration and migration</title><p>The process of neutrophils entering inflammatory tissues through the vascular endothelium is an important innate immune defense mechanism against infections as well as acute and chronic inflammatory diseases involving sepsis, trauma, ischemia, and reperfusion. Therefore, targeting neutrophil infiltration may be an effective means to improve the treatment of inflammation-related diseases&#160;[<xref rid="j_mr-2022-0047_ref_158" ref-type="bibr">158</xref>]. For instance, Liu and Cao et&#160;al. screened specific cationic lipid-assisted nanoparticles (CLANs) for optimized neutrophil targeting in high-fat diet (HFD)-induced type 2 diabetes (T2D) mice with chronic inflammation&#160;[<xref rid="j_mr-2022-0047_ref_159" ref-type="bibr">159</xref>]. A CRISPR-Cas9 plasmid with guide RNA targeting neutrophil elastase (NE) was packaged into the optimized CLAN (CLAN<sub>pCas9/gNE</sub>). In&#160;epididymal white adipose tissue (eWAT) and liver, CLAN<sub>pCas9/gNE</sub> was expeditiously internalized by neutrophils, at which point the NE gene was knocked down, significantly decreasing neutrophil infiltration and insulin resistance, and disturbing inflammation (<xref rid="j_mr-2022-0047_fig_007" ref-type="fig">Figure&#160;7A</xref>).</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_007" orientation="portrait"><label>Figure&#160;7:</label><caption><p>Nanoparticles for restraining the infiltration and migration of neutrophils. (A) Neutrophil NE gene was knocked down by the optimized CLAN<sub>pCas9/gNE</sub> for the treatment of HFD-induced T2D, significantly decreasing neutrophil infiltration and insulin resistance [<xref rid="j_mr-2022-0047_ref_159" ref-type="bibr">159</xref>]. (B) Platelet-mimetic nanoparticles were recognized by neutrophils through platelet membrane coating, and piceatannol delivered by nanoparticles could detach adherent neutrophils, thereby restraining the migration of neutrophils and reducing infiltration [<xref rid="j_mr-2022-0047_ref_162" ref-type="bibr">160</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_007.jpg"/></fig><p>In addition, Cruz et&#160;al. constructed an innovative nano-platform with &#945;1-antitrypsin-derived peptide to bind NE on activated neutrophils&#160;[<xref rid="j_mr-2022-0047_ref_160" ref-type="bibr">161</xref>]. This modification specifically anchors activated neutrophils and platelet-neutrophil aggregates to nanoparticles. Neutrophils play an important role in chemically-mediated inflammatory responses via myeloperoxidase (MPO) and inflammation triggered by traumatic brain injury (TBI). Yao et&#160;al. obtained nanodrugs targeting MPO and neutrophils (T-Hes) by modifying 5-hydroxytryptamine (5-HT) on nanoparticles carrying hesperidin. They confirmed that T-Hes targeted by neutrophils rapidly accumulate in the brain tissue, reducing the production of inflammatory factors, microglia, and astrocytes. T-Hes significantly enhanced drug retention and release, improving TBI treatment&#160;[<xref rid="j_mr-2022-0047_ref_161" ref-type="bibr">162</xref>].</p><p>Neutrophils prolifically infiltrate into ischemic areas of the brain and release ROS after acute ischemic stroke. Therefore, reducing neutrophil infiltration after acute ischemic stroke may be an effective treatment. Tang et&#160;al. constructed platelet-mimicking nanoparticles co-loaded with the spleen tyrosine kinase inhibitor piceatannol and the T2 contrast agent superparamagnetic iron oxide (SPIO)&#160;[<xref rid="j_mr-2022-0047_ref_162" ref-type="bibr">160</xref>]. The particles were recognized by neutrophils due to their platelet membrane coating, and the piceatannol caused adherent neutrophils to detach, thereby reducing infiltration and infarct size (<xref rid="j_mr-2022-0047_fig_007" ref-type="fig">Figure&#160;7B</xref>).</p></sec><sec id="j_mr-2022-0047_s_007_s_003"><title>Nano-engineered neutrophils or neutrophil derivatives</title><p>Live cells or derivatives, such as exosomes, have become attractive as pharmaceutical carriers because of their biocompatibility, low clearance rate, natural ability to penetrate physiological barriers, and specific biological characteristics of the source cells&#160;[<xref rid="j_mr-2022-0047_ref_163" ref-type="bibr">163</xref>]. For example, Wang et&#160;al. used neutrophil-exosomes (NEs-Exos) to carry doxorubicin (DOX) to glioma by taking advantage of their blood-brain barrier permeability, the inflammatory chemotaxis properties of neutrophils, and glioma-killing efficacy&#160;[<xref rid="j_mr-2022-0047_ref_164" ref-type="bibr">164</xref>]. To endow the exosomes with more functionality, Zhang et&#160;al. modified SPIO nanoparticles (SPIONs) with neutrophil exosomes (SPION-Ex) to achieve better tumor targeting efficacy than conventional NEs-Exos&#160;[<xref rid="j_mr-2022-0047_ref_165" ref-type="bibr">165</xref>].</p><p>Although endogenous living cells or exosomes inherit the native functions and features of the original cells, they typically do not meet the diverse needs of disease treatment and large-scale drug preparation due to their low levels of production and singular function. It may be possible to develop new multifunctional cellular drugs through nanoengineering strategies, which may provide new ideas for treating multiple diseases. Zhang et&#160;al. proposed the notion of cytopharmaceuticals, and physically modified neutrophils to carry out non-destructive loading of nanodrugs and to prepare neutrophil-based drugs that did not affect the physiological function and vitality of the neutrophils. This method has made breakthroughs in the therapy of orthotopic brain glioma in mice, postoperative chemotherapy, hyperthermia combined with chemotherapy for liver cancer, and radiotherapy combined with chemotherapy for gastric cancer. Compared with traditional targeted delivery systems, cyto-pharmaceuticals provide advantages in long circulation, targeting, and biocompatibility <italic toggle="yes">in&#160;vivo</italic>&#160;[<xref rid="j_mr-2022-0047_ref_068" ref-type="bibr">68</xref>]. Xue et&#160;al. constructed a novel autologous cell-mediated drug-delivery system utilizing neutrophils to pre-ingest paclitaxel (PTX)-loaded cationic liposomes (PTX-CL) with a positive surface charge <italic toggle="yes">in&#160;vitro</italic> (PTX-CL/NEs). PTX-CL/NEs were intravenously injected into mice with surgically resected gliomas. Inflammatory factors produced by the surgical site induced neutrophils to cross the BBB into the brain and infiltrate into the surrounding tumor cells. The PTX-CL/NEs were over-activated, releasing NETs while releasing the liposome PTX-CL. Then, the liposome PTX-CL effectively delivered the PTX to the tumor interior, thereby killing brain tumor cells and limiting tumor recurrence&#160;[<xref rid="j_mr-2022-0047_ref_163" ref-type="bibr">163</xref>].</p><p>Zhang et&#160;al. also developed a neutrophil membrane-coated polymer nanoparticle to treat rheumatoid arthritis&#160;[<xref rid="j_mr-2022-0047_ref_166" ref-type="bibr">166</xref>,&#160;<xref rid="j_mr-2022-0047_ref_167" ref-type="bibr">167</xref>]. These nanoparticles neutralize pro-inflammatory cytokines, alleviating synovial inflammation and providing robust cartilage protection against joint damage. There has been a lot of work based on neutrophil-derived membranes in cancer. For instance, Li et&#160;al. designed a pseudoneutrophil cytokine sponge (pCSs) by coating the outer surface of degradable polymer nanoparticles with activated neutrophil cell membranes&#160;[<xref rid="j_mr-2022-0047_ref_168" ref-type="bibr">168</xref>]. Receptors on the membrane surface adsorb and capture immunosuppressive cytokines, significantly inhibiting the expansion, recruitment, and activation of myelosuppressive cells, thus alleviating the immunosuppressive tumor microenvironment and enhancing the tumor-killing effect of T&#160;cells.</p></sec><sec id="j_mr-2022-0047_s_007_s_004"><title>Nanoparticles for regulating other granulocytes</title><p>When stimulated by allergens, mast cells, a type of granulocyte, activate ROS production, degranulation to release allergic mediators, and pathological responses, leading to the development of allergic diseases. Based on the narrow therapeutic time window of regulating mast cells, Lin et&#160;al. developed a novel mast cell nano-stabilizer based on ceria nanoparticles to achieve long-term prevention of allergic diseases&#160;[<xref rid="j_mr-2022-0047_ref_169" ref-type="bibr">169</xref>]. The nano-stabilizer continuously regulates degranulation-related phosphate signal cascades in allergen-stimulated mast cells to inhibit release of inflammatory mediators, thereby inhibiting the occurrence of an allergic response.</p><p>Eosinophils mediate the development of asthma by secreting a large number of inflammatory cytokines or programmed necrosis, which aggravates the condition. Sun et&#160;al. developed a ROS-responsive nanoparticle carrying Fedratinib (JAK2 inhibitor) with a modified Fc fragment of immunoglobulin G on the surface&#160;[<xref rid="j_mr-2022-0047_ref_170" ref-type="bibr">170</xref>]. By targeting the FcRn of lung airway epithelial cells, the cargo was delivered across the airway barrier through Fc/FcRn-mediated receptor transport to achieve lysosomal escape. Fedratinib was released after being cleaved by ROS in the inflammatory microenvironment, relieving eosinophilic asthma.</p></sec></sec><sec id="j_mr-2022-0047_s_008"><title>Nanoparticle-based strategies for B&#160;cell regulation</title><p>As a type of lymphocyte, B&#160;cells also develop in the bone marrow, which are involved in humoral immunity. After encountering the foreign substance, B&#160;cells can differentiate into plasma cells, with the ability of producing antigen-specific antibodies to fight infection and regulate inflammation, or directly secreting cytokines to support or modulate effector immune functions. At the same time, B&#160;cells generate memory B&#160;cells to protect against pathogen re-exposure. B&#160;cells can also serve as APCs leading to optimal antigen-specific T&#160;cell expansion&#160;[<xref rid="j_mr-2022-0047_ref_171" ref-type="bibr">171</xref>]. Regulating B&#160;cell function <italic toggle="yes">in&#160;vivo</italic> may have a profound impact on disease research, prevention, and treatment&#160;[<xref rid="j_mr-2022-0047_ref_172" ref-type="bibr">172</xref>].</p><sec id="j_mr-2022-0047_s_008_s_001"><title>Nanoparticles for disrupting B&#160;cell function</title><p>B&#160;cells also have important functions in the pathogenesis of&#160;autoimmune diseases. B&#160;cells promote autoimmunity by&#160;producing autoantibodies, acting as APCs, producing cytokines, and other mechanisms. Therefore, B&#160;cells are a promising therapeutic target for autoimmune diseases&#160;[<xref rid="j_mr-2022-0047_ref_173" ref-type="bibr">173</xref>].</p><p>Our group developed PEG-<italic toggle="yes">b</italic>-PLA or PEG-<italic toggle="yes">b</italic>-PLGA-based CLANs to deliver nucleic acids (<xref rid="j_mr-2022-0047_fig_008" ref-type="fig">Figure&#160;8A</xref>). To optimize CLAN delivery efficiency to B&#160;cells, we created a library of CLANs and compared them with different PEG-<italic toggle="yes">b</italic>-PLGA and cationic lipid formulations. By flow cytometry, we compared the uptake of CLAN by B&#160;cells in bone marrow, spleen, and lymph nodes, and screened for the best CLAN-40.30%NPB2.0 (40.30% PEG/PLGA and 2.0&#160;mg BHEM-Chol). The obtained CLAN can effectively deliver CRISPR-Cas9 plasmids to B&#160;cells <italic toggle="yes">in&#160;vivo</italic>, and was used to successfully treat rheumatoid arthritis in mice by knocking out BAFFR in B&#160;cells&#160;[<xref rid="j_mr-2022-0047_ref_174" ref-type="bibr">174</xref>]. We also delivered BTK siRNA via CLAN to treat rheumatoid arthritis in a CIA model and found that systemic administration of CLAN<sub>siBTK</sub> significantly reduced the expression of inflammatory cytokines and relieved symptoms of arthritis (<xref rid="j_mr-2022-0047_fig_008" ref-type="fig">Figure&#160;8B</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_175" ref-type="bibr">175</xref>].</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_008" orientation="portrait"><label>Figure&#160;8:</label><caption><p>Nanoparticle for regulating B&#160;cell function. (A) CLANs deliver CRISPR-Cas9 plasmid to B&#160;cells [<xref rid="j_mr-2022-0047_ref_174" ref-type="bibr">174</xref>]. (B) CLANs deliver BTK siRNA to B&#160;cells [<xref rid="j_mr-2022-0047_ref_175" ref-type="bibr">175</xref>]. (C) Env-trimer-conjugated liposomes activate B&#160;cell. The composition of the nanoparticles is shown in the figure [<xref rid="j_mr-2022-0047_ref_182" ref-type="bibr">176</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_008.jpg"/></fig></sec><sec id="j_mr-2022-0047_s_008_s_002"><title>Nanoparticles for activating or enhancing B&#160;cell function</title><p>Vaccines are an important means to fight infectious diseases. During antigen exposure resulting from vaccination, B&#160;cells rapidly proliferate and undergo somatic hypermutation to select better and more antigenically responsive B&#160;cell clones to produce high-affinity immunoglobulin-&#945; (IgA) and immunoglobulin-&#947; (IgG) antibodies. Activated B&#160;cells leave the germinal centers as plasma cells and memory B&#160;cells, protecting against reinfection for months to years. Therefore, efficient eliciting of B&#160;cell responses is of great importance for the development of vaccines against viruses&#160;[<xref rid="j_mr-2022-0047_ref_176" ref-type="bibr">177</xref>].</p><p>Temchura et&#160;al. developed biodegradable calcium phosphate nanoparticles displaying protein antigens on their surface and explored the efficacy of B&#160;cell activation after exposure to these nanoparticles&#160;[<xref rid="j_mr-2022-0047_ref_177" ref-type="bibr">178</xref>]. First, they studied calcium phosphate nanoparticles modified with model antigen Hen Egg Lysozyme (CaP-HEL). When CaP-HEL was co-incubated with mouse SW-HEL B&#160;cells, nearly 49% of the B&#160;cells bound to CaP-HEL and surface expression of CD69 and CD86 increased approximately 100-fold compared to free HEL. In order to increase the immunogenicity of CaP-HEL nanoparticles, they also modified TLR ligands on the surface of CaP-HEL&#160;[<xref rid="j_mr-2022-0047_ref_178" ref-type="bibr">179</xref>]. After injecting the nanoparticles into mice, they found that IgG levels were significantly elevated.</p><p>For highly variable influenza viruses, Kanekiyo et&#160;al. developed a mosaic array by co-localizing heterotypic influenza hemagglutinin antigens on a single nanoparticle&#160;[<xref rid="j_mr-2022-0047_ref_179" ref-type="bibr">180</xref>]. They linked different hemagglutinin RBD sequences to engineered ferritin sequences, and then transfected the RBD-ferritin plasmids into 293F cells. Four days after transfection, they collected the supernatant to obtain self-assembled RBD nanoparticles (RBD-np). This ferritin-based modular self-assembling nanoparticle system has been applied in many studies for influenza vaccines&#160;[<xref rid="j_mr-2022-0047_ref_180" ref-type="bibr">181</xref>,&#160;<xref rid="j_mr-2022-0047_ref_181" ref-type="bibr">182</xref>]. RBD-np carries different strains of influenza virus hemagglutinin antigens on its surface, effectively reducing the activation of strain-specific B&#160;cells and allowing selective engagement of B&#160;cells resistant to antigenic variation.</p><p>For HIV, which still has no effective drug, Wyatt et&#160;al. designed LNPs displaying well-ordered HIV Env spike trimers on their surface to serve as an HIV vaccine immunogen (<xref rid="j_mr-2022-0047_fig_008" ref-type="fig">Figure&#160;8C</xref>)&#160;[<xref rid="j_mr-2022-0047_ref_182" ref-type="bibr">176</xref>]. The liposomes were composed of DGPC, cholesterol, and DGS-NTA(Ni), and incubation with trimeric proteins yielded Env-trimer-conjugated liposomes. After incubation with Env-trimer-conjugated liposomes, CD69 expression increased, and more TNF-&#945; and IL-6 secretion was observed, indicating that Env-trimer-conjugated liposomes activated the B&#160;cells. When Env-trimer-conjugated liposomes was injected into C57BL/6 mice for 14&#160;days, germinal center B&#160;cells were also activated. In the HIV pseudovirus neutralization test, rabbits were immunized with soluble or Env-trimer-conjugated liposomes. Serum measurements showed that, compared with soluble trimers, the neutralization titer caused by Env-trimer-conjugated liposomes tended to increase.</p></sec></sec><sec id="j_mr-2022-0047_s_009"><title>Nanoparticle-based strategies for innate lymphocyte regulation</title><p>Natural killer cells, also known as NK cells or large granular lymphocytes, are a type of innate immune cell and perform a cytotoxic role in cellular immunity. NK cells develop and mature in bone marrow and secondary lymphoid tissues, including spleen, lymph nodes, and tonsils. NK cells are analogous to cytotoxic T&#160;cells and kill aberrant cells, but they do so without receptors for antigen recognition. In the absence of antigen specificity, NK cells have the ability to selectively recognize and kill stressed cells and cancer cells, allowing for a fast immune reaction&#160;[<xref rid="j_mr-2022-0047_ref_183" ref-type="bibr">183</xref>]. NK cells can also produce a variety of cytokines and chemokines&#160;[<xref rid="j_mr-2022-0047_ref_184" ref-type="bibr">184</xref>]. NK cells can be classified as CD56<sup>bright</sup> or CD56<sup>dim</sup>. CD56<sup>bright</sup> NK cells are the largest proportion of NK cells and mainly release cytokines, like T helper cells&#160;[<xref rid="j_mr-2022-0047_ref_185" ref-type="bibr">185</xref>]. CD56dim NK cells are characterized by their killing ability&#160;[<xref rid="j_mr-2022-0047_ref_186" ref-type="bibr">186</xref>]. Here we review direct NK cell targeting nanotechnology applications, including nanoparticle-mediated NK cell activation and a nano-engager for NK cells.</p><sec id="j_mr-2022-0047_s_009_s_001"><title>Nanoparticle-mediated NK cell activation</title><p>NK cells play important roles in cancer therapy, but poor infiltration and inhibition remain barriers to clinical translation that may be overcome by using nanoparticles. To direct NK cells to infiltrate tumors, Jang et&#160;al. used Cy5.5-conjugated Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub> nanoparticles to control human NK cells by an external magnetic field&#160;[<xref rid="j_mr-2022-0047_ref_187" ref-type="bibr">187</xref>]. NK-92MI cells were incubated with Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub> nanoparticles to allow uptake, then the nanoparticle-loaded NK cells were injected into a mouse model of B&#160;cell lymphoma. Under an external magnetic field, this strategy increased NK-92MI cell infiltration of the tumor by more than 17-fold (<xref rid="j_mr-2022-0047_fig_009" ref-type="fig">Figure&#160;9A</xref>). Similarly, polydopamine-coated magnetic nanoparticles directed NK cells to the tumor site to strengthen NK cell-mediated cancer therapy&#160;[<xref rid="j_mr-2022-0047_ref_188" ref-type="bibr">188</xref>]. To activate NK cells and enhance NK cell-mediated cancer therapy, Wu et&#160;al. developed cell membrane-encapsulated magnetic nanoparticles&#160;[<xref rid="j_mr-2022-0047_ref_189" ref-type="bibr">189</xref>]. Fe<sub>3</sub>O<sub>4</sub>@SiO<sub>2</sub> nanoparticles were coated with cancer cell membrane and used to stimulate NK cells with cancer-specific antigens, resulting in release of cytotoxic cytokines such as perforin and granzyme B to enhance antitumor efficacy in hepatoma tumor cells. Kim et&#160;al. reported a facile and efficient method to activate NK cells through cationic magnetic nanoparticles&#160;[<xref rid="j_mr-2022-0047_ref_190" ref-type="bibr">190</xref>]. Primary NK and NK-92MI cells were treated with cationic magnetic nanoparticles, and upregulated CCR4 and CXCR4 chemokine receptor expression (<xref rid="j_mr-2022-0047_fig_009" ref-type="fig">Figure&#160;9B</xref>). In a model of triple-negative breast cancer, nanoparticle-activated NK cells inhibited tumor growth.</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_009" orientation="portrait"><label>Figure&#160;9:</label><caption><p>Nanoparticle-mediated NK cell activation. (A) The Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub> nanoparticles modified with PET-silane and fluorescent dyes directed NK cells under an external magnetic field [<xref rid="j_mr-2022-0047_ref_187" ref-type="bibr">187</xref>]. (B) Cationic nanoparticle-mediated NK cell activation via regulation of CCR4 and CXCR4 [<xref rid="j_mr-2022-0047_ref_190" ref-type="bibr">190</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_009.jpg"/></fig><p>Other nanoparticles can also be used for NK cells activation. Loftus et&#160;al. developed a strategy to generate soluble nanoclusters of NK cell-activating antibodies using antibody-conjugated nanoscale graphene oxide as template&#160;[<xref rid="j_mr-2022-0047_ref_191" ref-type="bibr">191</xref>]. These nanoclusters mimicked a number of natural cell surface proteins, successfully stimulated NK cells, and induced cellular activation via the CD16 receptor. Nakamura et&#160;al. used a multifunctional envelope-type nanodevice (MEND) containing YSK12-C4 (YSK12-MEND) to transfect human immune cell lines with siRNA&#160;[<xref rid="j_mr-2022-0047_ref_192" ref-type="bibr">192</xref>]. In this work, Jurkat, THP-1, KG-1, and NK92 were transfected and showed 96, 96, 91, and 75% mRNA knockdown efficiencies, respectively. These results indicated that YSK12-MEND was suitable for delivering siRNA into immune cells, including NK cells. However, NK-92&#160;cell transfection yielded significant cytotoxicity. Nakamura et&#160;al. decreased the total amount of lipids in YSK12-C4, which was the cause of cytotoxicity in NK-92&#160;[<xref rid="j_mr-2022-0047_ref_193" ref-type="bibr">193</xref>]. This improved YSK12-MEND and demonstrated more potential ways to regulate NK cells.</p><p>Extracellular vesicles contain different proteins with&#160;natural structures. Oyer et&#160;al. developed a cancer cell&#160;membrane-derived particle for cytotoxic NK cell expansion&#160;[<xref rid="j_mr-2022-0047_ref_194" ref-type="bibr">194</xref>]. K562-mb21-4-1BBL cells, which express membrane-bound IL-21 and 4-1BB ligand, were prepared to generate PM21 particles, which showed highly efficient activation to produce 66-fold more human NK cells ex&#160;vivo, and 360-fold more <italic toggle="yes">in&#160;vivo</italic>.</p></sec><sec id="j_mr-2022-0047_s_009_s_002"><title>Nano-engager for regulating NK cells</title><p>Like cytotoxic T&#160;cells, NK cell-mediated cell killing depends on recognition of aberrant cells by NK cells. Bispecific or trispecific antibody have been used as engagers between NK cells and tumor cells&#160;[<xref rid="j_mr-2022-0047_ref_195" ref-type="bibr">195</xref>]. Nanotechnology provides a more flexible approach to direct NK cell interactions with target cells and enhance NK cell-mediated cytotoxicity. Au et&#160;al. reported a nanoparticle-based trispecific NK cell engager (nano-TriNKE) platform to promote NK cell-mediated cancer therapy&#160;[<xref rid="j_mr-2022-0047_ref_196" ref-type="bibr">196</xref>]. In this work, PEG-PLGA nanoparticles were functionalized with three types of antibodies including antibody targeting activating receptors, CD16 and 4-1BB, on&#160;NK cells and EGFR on tumor cells. The nano-TriNKE enhanced the interaction between NK cells and tumor cells by targeting their specific surface proteins and promoted NK&#160;cell activation through CD16 and 4-1BB receptors (<xref rid="j_mr-2022-0047_fig_010" ref-type="fig">Figure&#160;10A</xref>). The results revealed that nano-TriNKE activated NK cells more effectively than free antibodies, and improved tumor therapy in multiple tumor models. Jiang et&#160;al. developed a versatile imNA model that could be applied as a nano-engager for NK cells&#160;[<xref rid="j_mr-2022-0047_ref_076" ref-type="bibr">76</xref>]. To construct NK cell-targeting imNAs, antibodies targeting KLRG1 (killer-cell lectin-like receptor G1) and PD-L1 were immobilized onto anti-Fc antibody-functionalized nanoparticles (<xref rid="j_mr-2022-0047_fig_010" ref-type="fig">Figure&#160;10B</xref>). Anti-KLRG1 antibody served to block cadherin/KLRG1 signaling to enhance NK cell functions, and anti-PD-L1 antibody was used to bind tumor cells. This strategy significantly reduced metastatic melanoma formation in lung compared to free antibodies.</p><fig position="float" fig-type="figure" id="j_mr-2022-0047_fig_010" orientation="portrait"><label>Figure&#160;10:</label><caption><p>Nano-engager for NK cells. (A) EGFR-targeted nanoparticle-based trispecific NK cell engagers (nano-TriNKEs) (&#945;EGFR/&#945;CD16/&#945;4-1BB NPs) against EGFR-overexpressed cancer after systemic administration [<xref rid="j_mr-2022-0047_ref_196" ref-type="bibr">196</xref>]. (B) Nano-adaptor in NK cell-mediated cancer therapy [<xref rid="j_mr-2022-0047_ref_076" ref-type="bibr">76</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="j_mr-2022-0047_fig_010.jpg"/></fig></sec></sec><sec id="j_mr-2022-0047_s_010"><title>Conclusions and future perspectives</title><p>In summary, nanotechnology can improve the safety and efficacy of immunomodulatory compounds by altering their temporal and spatial release. Concentration and targeting of the dose to the appropriate site or cell type can improve therapeutic efficacy. Extended, controlled, localized drug release enables continuous reprogramming of the TME or post-surgery environment&#160;[<xref rid="j_mr-2022-0047_ref_197" ref-type="bibr">197</xref>]. Although nanoparticle-based regulation strategies are promising, especially for disease treatment, the current perception of their role in disease is not comprehensive, including the fate and state of nanoparticles <italic toggle="yes">in&#160;vivo</italic>, the potential influence in immune cell subtypes with different functions, and the transformation between subtypes. The activation and abundance of immune cells change dynamically through disease development and inflammation. Accurate immune intervention often depends on updating technology to achieve real-time dynamic exploration of cellular function or behavior. Targeting of immune cells <italic toggle="yes">in&#160;vivo</italic> requires appropriate and rational design of nanomedicines and increased targeting specificity to mitigate nonspecific targeting, and the selection of drugs and carriers that do not affect cellular function should also be considered. Researchers can control the targeting functions of nanoparticles to different tissues or immune cells by adjusting the characteristics of nanoparticles, such as the types and proportions of lipids, which can be manipulated to target different tissues&#160;[<xref rid="j_mr-2022-0047_ref_198" ref-type="bibr">198</xref>]. In addition, specific nucleic acid barcodes can be encapsulated into nanoparticles for high-throughput screening by deep sequencing of the barcodes, thereby finding the optimal nanoparticle for predicting the therapeutic potency of anticancer medicines in a personalized manner&#160;[<xref rid="j_mr-2022-0047_ref_199" ref-type="bibr">199</xref>]. According to the location and characteristics of the diseases, it is promising to achieve the purpose of treating different diseases by more precisely targeting nanoparticles.</p><p>For <italic toggle="yes">in&#160;vitro</italic> engineered immune cells, the yield, activity, and safety of functional proteins require further attention. Manufacturing of clinical grade materials remains a key consideration that cannot be ignored. The formulation should be designed with a view to conversion to GMP standards. Particles, devices, and cells require reproducible and scalable chemistry, manufacturing, and control, so simplicity is extremely valuable&#160;[<xref rid="j_mr-2022-0047_ref_029" ref-type="bibr">28</xref>]. The convergence of cancer immunotherapy, nanotechnology, and bioengineering is coming of age and could affect patient lives soon. To accelerate the clinical translation of nanocarriers that regulate immune cells, it is essential to engage researchers across the fields of materials science, engineering, pharmacology, and immunology. In order to rapidly screen nanomedicine with clinical application value, organoid technology platform can be used to achieve fast, accurate and high-throughput screening&#160;[<xref rid="j_mr-2022-0047_ref_200" ref-type="bibr">200</xref>].</p></sec></body><back><fn-group><fn fn-type="financial-disclosure" id="j_mr-2022-0047_fn_001"><p>
<bold>Research funding:</bold> This work was supported by the National Key R&amp;D Program of China (2022YFB3808100), the National Natural Science Foundation of China (82072048, 52130301, and 32271442), Guangdong Basic and Applied Basic Research Foundation (2022B1515020025), the Science and Technology Program of Guangzhou, China (202103030004), and the Fundamental Research Funds for the Central Universities (2022ZYGXZR102).</p></fn><fn fn-type="con" id="j_mr-2022-0047_fn_002"><p>
<bold>Author contributions:</bold> All authors have accepted responsibility for the entire content of this manuscript and approved its submission.</p></fn><fn fn-type="COI-statement" id="j_mr-2022-0047_fn_003"><p>
Conflicts of interests: Authors state no conflict of interest.</p></fn><fn fn-type="other" id="j_mr-2022-0047_fn_004"><p>
<bold>Ethical approval:</bold> Not applicable.</p></fn></fn-group><ref-list id="j_mr-2022-0047_reflist_001"><title>References</title><ref id="j_mr-2022-0047_ref_001"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>B</given-names></name></person-group><article-title>An overview of the immune system</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1777</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(00)04904-7</pub-id><pub-id pub-id-type="pmid">11403834</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_002"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Immunomodulatory nanosystems</article-title><source>Adv Sci</source><year>2019</year><volume>6</volume><elocation-id>1900101</elocation-id><pub-id pub-id-type="doi">10.1002/advs.201900101</pub-id><pub-id pub-id-type="pmcid">PMC6724480</pub-id><pub-id pub-id-type="pmid">31508270</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_003"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Dey</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Nanomaterials for cancer therapy: current progress and perspectives</article-title><source>J Hematol Oncol</source><year>2021</year><volume>14</volume><fpage>85</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01096-0</pub-id><pub-id pub-id-type="pmid">34059100</pub-id><pub-id pub-id-type="pmcid">PMC8165984</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_004"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foulkes</surname><given-names>R</given-names></name><name name-style="western"><surname>Man</surname><given-names>E</given-names></name><name name-style="western"><surname>Thind</surname><given-names>J</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>S</given-names></name><name name-style="western"><surname>Joy</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoskins</surname><given-names>C</given-names></name></person-group><article-title>The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives</article-title><source>Biomater Sci</source><year>2020</year><volume>8</volume><fpage>4653</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1039/d0bm00558d</pub-id><pub-id pub-id-type="pmid">32672255</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_005"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngobili</surname><given-names>TA</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>MA</given-names></name></person-group><article-title>Nanoparticles and direct immunosuppression</article-title><source>Exp Biol Med</source><year>2016</year><volume>241</volume><fpage>1064</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1177/1535370216650053</pub-id><pub-id pub-id-type="pmcid">PMC4950368</pub-id><pub-id pub-id-type="pmid">27229901</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_006"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Merlin</surname><given-names>D</given-names></name></person-group><article-title>Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives</article-title><source>Int J Nanomed</source><year>2019</year><volume>14</volume><fpage>8875</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2147/ijn.s210315</pub-id><pub-id pub-id-type="pmcid">PMC6859086</pub-id><pub-id pub-id-type="pmid">32009785</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_007"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Dane</surname><given-names>EL</given-names></name></person-group><article-title>Enhancing cancer immunotherapy with nanomedicine</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>321</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0269-6</pub-id><pub-id pub-id-type="pmid">32005979</pub-id><pub-id pub-id-type="pmcid">PMC7536618</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_008"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Dom&#237;nguez-Andr&#233;s</surname><given-names>J</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>LB</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>375</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_009"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akar-Ghibril</surname><given-names>N</given-names></name></person-group><article-title>Defects of the innate immune system and related immune deficiencies</article-title><source>Clin Rev Allergy Immunol</source><year>2022</year><volume>63</volume><fpage>36</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s12016-021-08885-y</pub-id><pub-id pub-id-type="pmid">34417936</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_010"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>The innate immune signaling in cancer and cardiometabolic diseases: friends or foes?</article-title><source>Cancer Lett</source><year>2017</year><volume>387</volume><fpage>46</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.06.004</pub-id><pub-id pub-id-type="pmid">27339326</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_011"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Place</surname><given-names>DE</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>T-D</given-names></name></person-group><article-title>The innate immune system and cell death in autoinflammatory and autoimmune disease</article-title><source>Curr Opin Immunol</source><year>2020</year><volume>67</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2020.10.013</pub-id><pub-id pub-id-type="pmid">33242752</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_012"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><article-title>Cancer immunotherapy using checkpoint blockade</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1350</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id><pub-id pub-id-type="pmid">29567705</pub-id><pub-id pub-id-type="pmcid">PMC7391259</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_013"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J</given-names></name><name name-style="western"><surname>Ambalavanan</surname><given-names>P</given-names></name><name name-style="western"><surname>Yamanouchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Singha</surname><given-names>S</given-names></name><name name-style="western"><surname>Fandos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Expanding antigen-specific regulatory networks to treat autoimmunity</article-title><source>Nature</source><year>2016</year><volume>530</volume><fpage>434</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nature16962</pub-id><pub-id pub-id-type="pmid">26886799</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_014"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haist</surname><given-names>M</given-names></name><name name-style="western"><surname>Stege</surname><given-names>H</given-names></name><name name-style="western"><surname>Grabbe</surname><given-names>S</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M</given-names></name></person-group><article-title>The functional crosstalk between myeloid-derived suppressor cells and regulatory T&#160;cells within the immunosuppressive tumor microenvironment</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>210</fpage><pub-id pub-id-type="doi">10.3390/cancers13020210</pub-id><pub-id pub-id-type="pmid">33430105</pub-id><pub-id pub-id-type="pmcid">PMC7827203</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_015"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galdiero</surname><given-names>MR</given-names></name><name name-style="western"><surname>Bonavita</surname><given-names>E</given-names></name><name name-style="western"><surname>Barajon</surname><given-names>I</given-names></name><name name-style="western"><surname>Garlanda</surname><given-names>C</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Jaillon</surname><given-names>S</given-names></name></person-group><article-title>Tumor associated macrophages and neutrophils in cancer</article-title><source>Immunobiology</source><year>2013</year><volume>218</volume><fpage>1402</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2013.06.003</pub-id><pub-id pub-id-type="pmid">23891329</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_016"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonnenberg</surname><given-names>GF</given-names></name><name name-style="western"><surname>Hepworth</surname><given-names>MR</given-names></name></person-group><article-title>Functional interactions between innate lymphoid cells and adaptive immunity</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><fpage>599</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0194-8</pub-id><pub-id pub-id-type="pmid">31350531</pub-id><pub-id pub-id-type="pmcid">PMC6982279</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_017"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thommen</surname><given-names>DS</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>TN</given-names></name></person-group><article-title>T&#160;cell dysfunction in cancer</article-title><source>Cancer Cell</source><year>2018</year><volume>33</volume><fpage>547</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.012</pub-id><pub-id pub-id-type="pmid">29634943</pub-id><pub-id pub-id-type="pmcid">PMC7116508</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_019"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdon</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Mulazzani</surname><given-names>M</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>MR</given-names></name></person-group><article-title>Cellular and molecular mechanisms of CD8(+) T&#160;cell differentiation, dysfunction and exhaustion</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7357</fpage><pub-id pub-id-type="doi">10.3390/ijms21197357</pub-id><pub-id pub-id-type="pmid">33027962</pub-id><pub-id pub-id-type="pmcid">PMC7582856</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_020"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linette</surname><given-names>GP</given-names></name><name name-style="western"><surname>Carreno</surname><given-names>BM</given-names></name></person-group><article-title>Tumor-infiltrating lymphocytes in the checkpoint inhibitor era</article-title><source>Curr Hematol Malig Rep</source><year>2019</year><volume>14</volume><fpage>286</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1007/s11899-019-00523-x</pub-id><pub-id pub-id-type="pmid">31187421</pub-id><pub-id pub-id-type="pmcid">PMC6642683</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_021"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JS</given-names></name><name name-style="western"><surname>Teng</surname><given-names>MW</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer immunoediting and resistance to T cell-based immunotherapy</article-title><source>Nat Rev Clin Oncol</source><year>2019</year><volume>16</volume><fpage>151</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/s41571-018-0142-8</pub-id><pub-id pub-id-type="pmid">30523282</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_022"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelhard</surname><given-names>V</given-names></name><name name-style="western"><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>BH</given-names></name><name name-style="western"><surname>Willard-Gallo</surname><given-names>K</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>TC</given-names></name><etal/></person-group><article-title>B&#160;cells and cancer</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1293</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.09.007</pub-id><pub-id pub-id-type="pmid">34597591</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_023"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Ly</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Tumor-infiltrating B&#160;cells: their role and application in anti-tumor immunity in lung cancer</article-title><source>Cell Mol Immunol</source><year>2019</year><volume>16</volume><fpage>6</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/s41423-018-0027-x</pub-id><pub-id pub-id-type="pmid">29628498</pub-id><pub-id pub-id-type="pmcid">PMC6318290</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_024"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Chan</surname><given-names>HL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name></person-group><article-title>Immune checkpoint inhibitors: basics and challenges</article-title><source>Curr Med Chem</source><year>2019</year><volume>26</volume><fpage>3009</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170804143706</pub-id><pub-id pub-id-type="pmid">28782469</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_025"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marin-Acevedo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kimbrough</surname><given-names>EO</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y</given-names></name></person-group><article-title>Next generation of immune checkpoint inhibitors and beyond</article-title><source>J Hematol Oncol</source><year>2021</year><volume>14</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01056-8</pub-id><pub-id pub-id-type="pmid">33741032</pub-id><pub-id pub-id-type="pmcid">PMC7977302</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_026"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>DB</given-names></name></person-group><article-title>Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><fpage>306</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0805-8</pub-id><pub-id pub-id-type="pmid">31730012</pub-id><pub-id pub-id-type="pmcid">PMC6858629</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_027"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esfahani</surname><given-names>K</given-names></name><name name-style="western"><surname>Elkrief</surname><given-names>A</given-names></name><name name-style="western"><surname>Calabrese</surname><given-names>C</given-names></name><name name-style="western"><surname>Lapointe</surname><given-names>R</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>M</given-names></name><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Moving towards personalized treatments of immune-related adverse events</article-title><source>Nat Rev Clin Oncol</source><year>2020</year><volume>17</volume><fpage>504</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-0352-8</pub-id><pub-id pub-id-type="pmid">32246128</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_028"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bluestone</surname><given-names>JA</given-names></name><name name-style="western"><surname>Young</surname><given-names>A</given-names></name></person-group><article-title>Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines</article-title><source>Trends Immunol</source><year>2021</year><volume>42</volume><fpage>293</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.it.2021.02.006</pub-id><pub-id pub-id-type="pmid">33714688</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_029"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>MS</given-names></name></person-group><article-title>Improving cancer immunotherapy through nanotechnology</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><fpage>587</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0186-9</pub-id><pub-id pub-id-type="pmid">31492927</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_030"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bockamp</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosigkeit</surname><given-names>S</given-names></name><name name-style="western"><surname>Siegl</surname><given-names>D</given-names></name><name name-style="western"><surname>Schuppan</surname><given-names>D</given-names></name></person-group><article-title>Nano-enhanced cancer immunotherapy: immunology encounters nanotechnology</article-title><source>Cells</source><year>2020</year><volume>9</volume><fpage>2102</fpage><pub-id pub-id-type="doi">10.3390/cells9092102</pub-id><pub-id pub-id-type="pmid">32942725</pub-id><pub-id pub-id-type="pmcid">PMC7565449</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_031"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germain</surname><given-names>RN</given-names></name></person-group><article-title>T-cell development and the CD4-CD8 lineage decision</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><fpage>309</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nri798</pub-id><pub-id pub-id-type="pmid">12033737</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_032"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>BV</given-names></name><name name-style="western"><surname>Connors</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>Human T&#160;cell development, localization, and function throughout life</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>202</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.01.007</pub-id><pub-id pub-id-type="pmid">29466753</pub-id><pub-id pub-id-type="pmcid">PMC5826622</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_018"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philip</surname><given-names>M</given-names></name><name name-style="western"><surname>Schietinger</surname><given-names>A</given-names></name></person-group><article-title>CD8(+) T&#160;cell differentiation and dysfunction in cancer</article-title><source>Nat Rev Immunol</source><year>2022</year><volume>22</volume><fpage>209</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00574-3</pub-id><pub-id pub-id-type="pmid">34253904</pub-id><pub-id pub-id-type="pmcid">PMC9792152</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_033"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luckheeram</surname><given-names>RV</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>Verma</surname><given-names>AD</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B</given-names></name></person-group><article-title>CD4(+)T&#160;cells: differentiation and functions</article-title><source>Clin Dev Immunol</source><year>2012</year><volume>2012</volume><elocation-id>925135</elocation-id><pub-id pub-id-type="doi">10.1155/2012/925135</pub-id><pub-id pub-id-type="pmid">22474485</pub-id><pub-id pub-id-type="pmcid">PMC3312336</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_034"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdalla</surname><given-names>AM</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>MW</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name></person-group><article-title>Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>533</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.7150/thno.21674</pub-id><pub-id pub-id-type="pmid">29290825</pub-id><pub-id pub-id-type="pmcid">PMC5743565</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_035"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>AS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>DKY</given-names></name><name name-style="western"><surname>Koshy</surname><given-names>ST</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>DJ</given-names></name></person-group><article-title>Scaffolds that mimic antigen-presenting cells enable ex&#160;vivo expansion of primary T&#160;cells</article-title><source>Nat Biotechnol</source><year>2018</year><volume>36</volume><fpage>160</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nbt.4047</pub-id><pub-id pub-id-type="pmid">29334370</pub-id><pub-id pub-id-type="pmcid">PMC5801009</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_036"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmides</surname><given-names>AK</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>JW</given-names></name><name name-style="western"><surname>Aje</surname><given-names>K</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>KN</given-names></name><name name-style="western"><surname>Green</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma</article-title><source>Biomaterials</source><year>2017</year><volume>118</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.11.038</pub-id><pub-id pub-id-type="pmid">27940380</pub-id><pub-id pub-id-type="pmcid">PMC5207804</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_037"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Mai</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T&#160;cell activation and antigen-specific immune responses</article-title><source>Pharm Res (N Y)</source><year>2013</year><volume>30</volume><fpage>60</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s11095-012-0849-7</pub-id><pub-id pub-id-type="pmid">22878683</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_038"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>WA</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SA</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>CS</given-names></name><name name-style="western"><surname>Dranoff</surname><given-names>G</given-names></name><etal/></person-group><article-title>Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in&#160;vivo and increase vaccine efficacy</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/nbt.3071</pub-id><pub-id pub-id-type="pmid">25485616</pub-id><pub-id pub-id-type="pmcid">PMC4318563</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_039"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perica</surname><given-names>K</given-names></name><name name-style="western"><surname>Tu</surname><given-names>A</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A</given-names></name><name name-style="western"><surname>Bieler</surname><given-names>JG</given-names></name><name name-style="western"><surname>Edidin</surname><given-names>M</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>JP</given-names></name></person-group><article-title>Magnetic field-induced T&#160;cell receptor clustering by nanoparticles enhances T&#160;cell activation and stimulates antitumor activity</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>2252</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1021/nn405520d</pub-id><pub-id pub-id-type="pmid">24564881</pub-id><pub-id pub-id-type="pmcid">PMC4004316</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_040"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Florez</surname><given-names>L</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>CP</given-names></name><name name-style="western"><surname>Koynov</surname><given-names>K</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K</given-names></name><etal/></person-group><article-title>How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells</article-title><source>Small</source><year>2012</year><volume>8</volume><fpage>2222</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/smll.201102002</pub-id><pub-id pub-id-type="pmid">22528663</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_041"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barua</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kolhar</surname><given-names>P</given-names></name><name name-style="western"><surname>Wakankar</surname><given-names>A</given-names></name><name name-style="western"><surname>Gokarn</surname><given-names>YR</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S</given-names></name></person-group><article-title>Particle shape enhances specificity of antibody-displaying nanoparticles</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>3270</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216893110</pub-id><pub-id pub-id-type="pmid">23401509</pub-id><pub-id pub-id-type="pmcid">PMC3587278</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_042"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sunshine</surname><given-names>JC</given-names></name><name name-style="western"><surname>Perica</surname><given-names>K</given-names></name><name name-style="western"><surname>Kosmides</surname><given-names>AK</given-names></name><name name-style="western"><surname>Aje</surname><given-names>K</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation</article-title><source>Small</source><year>2015</year><volume>11</volume><fpage>1519</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/smll.201402369</pub-id><pub-id pub-id-type="pmid">25641795</pub-id><pub-id pub-id-type="pmcid">PMC4529071</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_043"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hickey</surname><given-names>JW</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>FP</given-names></name><name name-style="western"><surname>Howard</surname><given-names>GP</given-names></name><name name-style="western"><surname>Mao</surname><given-names>HQ</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>JP</given-names></name></person-group><article-title>Biologically inspired design of nanoparticle artificial antigen-presenting cells for immunomodulation</article-title><source>Nano Lett</source><year>2017</year><volume>17</volume><fpage>7045</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.7b03734</pub-id><pub-id pub-id-type="pmid">28994285</pub-id><pub-id pub-id-type="pmcid">PMC6709596</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_044"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chekuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>AV</given-names></name><etal/></person-group><article-title>Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity</article-title><source>Adv Mater</source><year>2020</year><volume>32</volume><elocation-id>e2001808</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202001808</pub-id><pub-id pub-id-type="pmid">32538494</pub-id><pub-id pub-id-type="pmcid">PMC7669572</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_045"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J</given-names></name><name name-style="western"><surname>Ambalavanan</surname><given-names>P</given-names></name><name name-style="western"><surname>Yamanouchi</surname><given-names>J</given-names></name><name name-style="western"><surname>Singha</surname><given-names>S</given-names></name><name name-style="western"><surname>Fandos</surname><given-names>C</given-names></name><etal/></person-group><article-title>Expanding antigen-specific regulatory networks to treat autoimmunity</article-title><source>Nature</source><year>2016</year><volume>530</volume><fpage>434</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/nature16962</pub-id><pub-id pub-id-type="pmid">26886799</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_046"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singha</surname><given-names>S</given-names></name><name name-style="western"><surname>Shao</surname><given-names>K</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Clemente-Casares</surname><given-names>X</given-names></name><name name-style="western"><surname>Sole</surname><given-names>P</given-names></name><name name-style="western"><surname>Clemente</surname><given-names>A</given-names></name><etal/></person-group><article-title>Peptide-MHC-based nanomedicines for autoimmunity function as T-cell receptor microclustering devices</article-title><source>Nat Nanotechnol</source><year>2017</year><volume>12</volume><fpage>701</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/nnano.2017.56</pub-id><pub-id pub-id-type="pmid">28436959</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_047"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>D</given-names></name><name name-style="western"><surname>Rae</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>AP</given-names></name><name name-style="western"><surname>Parton</surname><given-names>RG</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Human immune cell targeting of protein nanoparticles--caveospheres</article-title><source>Nanoscale</source><year>2016</year><volume>8</volume><fpage>8255</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1039/c6nr00506c</pub-id><pub-id pub-id-type="pmid">27031090</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_048"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>De Rose</surname><given-names>R</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>AP</given-names></name><name name-style="western"><surname>Czuba</surname><given-names>EI</given-names></name><name name-style="western"><surname>Khor</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Thiol-reactive star polymers display enhanced association with distinct human blood components</article-title><source>ACS Appl Mater Interfaces</source><year>2017</year><volume>9</volume><fpage>12182</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1021/acsami.6b15942</pub-id><pub-id pub-id-type="pmid">28338321</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_049"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivaram</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wardiana</surname><given-names>A</given-names></name><name name-style="western"><surname>Alcantara</surname><given-names>S</given-names></name><name name-style="western"><surname>Sonderegger</surname><given-names>SE</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>NL</given-names></name><name name-style="western"><surname>Houston</surname><given-names>ZH</given-names></name><etal/></person-group><article-title>Controlling the biological fate of micellar nanoparticles: balancing stealth and targeting</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>13739</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c06033</pub-id><pub-id pub-id-type="pmid">32936613</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_050"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CF</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><name name-style="western"><surname>Du</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Restoring anti-tumor functions of T&#160;cells via nanoparticle-mediated immune checkpoint modulation</article-title><source>J Contr Release</source><year>2016</year><volume>231</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.01.044</pub-id><pub-id pub-id-type="pmid">26829099</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_051"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huq</surname><given-names>R</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>EL</given-names></name><name name-style="western"><surname>Sikkema</surname><given-names>WK</given-names></name><name name-style="western"><surname>Nilewski</surname><given-names>LG</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><elocation-id>33808</elocation-id><pub-id pub-id-type="doi">10.1038/srep33808</pub-id><pub-id pub-id-type="pmid">27654170</pub-id><pub-id pub-id-type="pmcid">PMC5031970</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_052"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vis</surname><given-names>B</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>RE</given-names></name><name name-style="western"><surname>Faria</surname><given-names>N</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>C</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>H</given-names></name><name name-style="western"><surname>Pele</surname><given-names>L</given-names></name><etal/></person-group><article-title>Non-functionalized ultrasmall silica nanoparticles directly and size-selectively activate T&#160;cells</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>10843</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b03363</pub-id><pub-id pub-id-type="pmid">30346692</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_053"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiramanas</surname><given-names>R</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Simon</surname><given-names>J</given-names></name><name name-style="western"><surname>Landfester</surname><given-names>K</given-names></name><name name-style="western"><surname>Mailander</surname><given-names>V</given-names></name></person-group><article-title>Silica Nanocapsules with different sizes and physicochemical properties as suitable nanocarriers for uptake in T-cells</article-title><source>Int J Nanomed</source><year>2020</year><volume>15</volume><fpage>6069</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.2147/ijn.s246322</pub-id><pub-id pub-id-type="pmcid">PMC7439283</pub-id><pub-id pub-id-type="pmid">32884263</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_054"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabujew</surname><given-names>I</given-names></name><name name-style="western"><surname>Willig</surname><given-names>M</given-names></name><name name-style="western"><surname>Leber</surname><given-names>N</given-names></name><name name-style="western"><surname>Freidel</surname><given-names>C</given-names></name><name name-style="western"><surname>Negwer</surname><given-names>I</given-names></name><name name-style="western"><surname>Koynov</surname><given-names>K</given-names></name><etal/></person-group><article-title>Overcoming the barrier of CD8(+)T&#160;cells: two types of nano-sized carriers for siRNA transport</article-title><source>Acta Biomater</source><year>2019</year><volume>100</volume><fpage>338</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.10.006</pub-id><pub-id pub-id-type="pmid">31586726</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_055"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinauer</surname><given-names>N</given-names></name><name name-style="western"><surname>Balthasar</surname><given-names>S</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Kreuter</surname><given-names>J</given-names></name><name name-style="western"><surname>Langer</surname><given-names>K</given-names></name><name name-style="western"><surname>von Briesen</surname><given-names>H</given-names></name></person-group><article-title>Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes</article-title><source>Biomaterials</source><year>2005</year><volume>26</volume><fpage>5898</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2005.02.038</pub-id><pub-id pub-id-type="pmid">15949555</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_056"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kheirolomoom</surname><given-names>A</given-names></name><name name-style="western"><surname>Kare</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>ES</given-names></name><name name-style="western"><surname>Paulmurugan</surname><given-names>R</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Baikoghli</surname><given-names>M</given-names></name><etal/></person-group><article-title>In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift</article-title><source>Biomaterials</source><year>2022</year><volume>281</volume><elocation-id>121339</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121339</pub-id><pub-id pub-id-type="pmid">35078042</pub-id><pub-id pub-id-type="pmcid">PMC8892572</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_057"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramishetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Kedmi</surname><given-names>R</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>M</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>F</given-names></name><name name-style="western"><surname>Sprague</surname><given-names>AG</given-names></name><name name-style="western"><surname>Godin</surname><given-names>B</given-names></name><etal/></person-group><article-title>Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>6706</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b02796</pub-id><pub-id pub-id-type="pmid">26042619</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_058"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tombacz</surname><given-names>I</given-names></name><name name-style="western"><surname>Laczko</surname><given-names>D</given-names></name><name name-style="western"><surname>Shahnawaz</surname><given-names>H</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Natesan</surname><given-names>A</given-names></name><name name-style="western"><surname>Yadegari</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly efficient CD4+ T&#160;cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs</article-title><source>Mol Ther</source><year>2021</year><volume>29</volume><fpage>3293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2021.06.004</pub-id><pub-id pub-id-type="pmid">34091054</pub-id><pub-id pub-id-type="pmcid">PMC8571164</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_059"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Yun</surname><given-names>KS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CS</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ban</surname><given-names>HS</given-names></name><name name-style="western"><surname>Rhim</surname><given-names>T</given-names></name><etal/></person-group><article-title>T cell-specific siRNA delivery using antibody-conjugated chitosan nanoparticles</article-title><source>Bioconjugate Chem</source><year>2012</year><volume>23</volume><fpage>1174</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1021/bc2006219</pub-id><pub-id pub-id-type="pmid">22607555</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_060"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YS</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Bekdemir</surname><given-names>A</given-names></name><name name-style="western"><surname>Dichwalkar</surname><given-names>TM</given-names></name><name name-style="western"><surname>Noh</surname><given-names>MM</given-names></name><name name-style="western"><surname>Watson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Targeting small molecule drugs to T&#160;cells with antibody-directed cell-penetrating gold nanoparticles</article-title><source>Biomater Sci</source><year>2018</year><volume>7</volume><fpage>113</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1039/c8bm01208c</pub-id><pub-id pub-id-type="pmid">30444251</pub-id><pub-id pub-id-type="pmcid">PMC6310171</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_061"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nawaz</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yiqiao</surname><given-names>H</given-names></name><etal/></person-group><article-title>AAV-mediated in&#160;vivo CAR gene therapy for targeting human T-cell leukemia</article-title><source>Blood Cancer J</source><year>2021</year><volume>11</volume><fpage>119</fpage><pub-id pub-id-type="doi">10.1038/s41408-021-00508-1</pub-id><pub-id pub-id-type="pmid">34162832</pub-id><pub-id pub-id-type="pmcid">PMC8222347</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_062"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TT</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>SB</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>HF</given-names></name><name name-style="western"><surname>McKnight</surname><given-names>LE</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Reiman</surname><given-names>D</given-names></name><etal/></person-group><article-title>In situ programming of leukaemia-specific T&#160;cells using synthetic DNA nanocarriers</article-title><source>Nat Nanotechnol</source><year>2017</year><volume>12</volume><fpage>813</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nnano.2017.57</pub-id><pub-id pub-id-type="pmid">28416815</pub-id><pub-id pub-id-type="pmcid">PMC5646367</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_063"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moffett</surname><given-names>HF</given-names></name><name name-style="western"><surname>Coon</surname><given-names>ME</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>S</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>SB</given-names></name><name name-style="western"><surname>McKnight</surname><given-names>L</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>389</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00505-8</pub-id><pub-id pub-id-type="pmid">28855514</pub-id><pub-id pub-id-type="pmcid">PMC5577173</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_064"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parayath</surname><given-names>NN</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>SB</given-names></name><name name-style="western"><surname>Koehne</surname><given-names>AL</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>PS</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>MT</given-names></name></person-group><article-title>In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T&#160;cells in&#160;vivo</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>6080</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19486-2</pub-id><pub-id pub-id-type="pmid">33247092</pub-id><pub-id pub-id-type="pmcid">PMC7695830</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_065"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moon</surname><given-names>E</given-names></name><name name-style="western"><surname>Carpenito</surname><given-names>C</given-names></name><name name-style="western"><surname>Paulos</surname><given-names>CM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Multiple injections of electroporated autologous T&#160;cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>9053</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-10-2880</pub-id><pub-id pub-id-type="pmid">20926399</pub-id><pub-id pub-id-type="pmcid">PMC2982929</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_066"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillmore</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gane</surname><given-names>E</given-names></name><name name-style="western"><surname>Taubel</surname><given-names>J</given-names></name><name name-style="western"><surname>Kao</surname><given-names>J</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>M</given-names></name><name name-style="western"><surname>Maitland</surname><given-names>ML</given-names></name><etal/></person-group><article-title>CRISPR-Cas9 in&#160;vivo gene editing for transthyretin amyloidosis</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1056/nejmoa2107454</pub-id><pub-id pub-id-type="pmid">34215024</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_067"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krienke</surname><given-names>C</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>L</given-names></name><name name-style="western"><surname>Diken</surname><given-names>E</given-names></name><name name-style="western"><surname>Streuber</surname><given-names>M</given-names></name><name name-style="western"><surname>Kirchhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>Bukur</surname><given-names>T</given-names></name><etal/></person-group><article-title>A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.aay3638</pub-id><pub-id pub-id-type="pmid">33414215</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_068"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billingsley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N</given-names></name><name name-style="western"><surname>Ravikumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>June</surname><given-names>CH</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name></person-group><article-title>Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T&#160;cell engineering</article-title><source>Nano Lett</source><year>2020</year><volume>20</volume><fpage>1578</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b04246</pub-id><pub-id pub-id-type="pmid">31951421</pub-id><pub-id pub-id-type="pmcid">PMC7313236</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_069"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rurik</surname><given-names>JG</given-names></name><name name-style="western"><surname>Tombacz</surname><given-names>I</given-names></name><name name-style="western"><surname>Yadegari</surname><given-names>A</given-names></name><name name-style="western"><surname>Mendez Fernandez</surname><given-names>PO</given-names></name><name name-style="western"><surname>Shewale</surname><given-names>SV</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>CAR T&#160;cells produced in&#160;vivo to treat cardiac injury</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>91</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1126/science.abm0594</pub-id><pub-id pub-id-type="pmid">34990237</pub-id><pub-id pub-id-type="pmcid">PMC9983611</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_070"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><article-title>Cancer immunotherapy using checkpoint blockade</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1350</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id><pub-id pub-id-type="pmid">29567705</pub-id><pub-id pub-id-type="pmcid">PMC7391259</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_071"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A</given-names></name></person-group><article-title>Primary, adaptive, and acquired resistance to cancer immunotherapy</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>707</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id><pub-id pub-id-type="pmid">28187290</pub-id><pub-id pub-id-type="pmcid">PMC5391692</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_072"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>WE</given-names></name><name name-style="western"><surname>Storm</surname><given-names>G</given-names></name></person-group><article-title>Sheddable coatings for long-circulating nanoparticles</article-title><source>Pharm Res (N Y)</source><year>2008</year><volume>25</volume><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s11095-007-9348-7</pub-id><pub-id pub-id-type="pmcid">PMC2190344</pub-id><pub-id pub-id-type="pmid">17551809</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_073"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fourniols</surname><given-names>T</given-names></name><name name-style="western"><surname>Labrak</surname><given-names>Y</given-names></name><name name-style="western"><surname>Preat</surname><given-names>V</given-names></name><name name-style="western"><surname>Beloqui</surname><given-names>A</given-names></name><name name-style="western"><surname>des Rieux</surname><given-names>A</given-names></name></person-group><article-title>Surface modification of lipid-based nanoparticles</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><fpage>7168</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c02347</pub-id><pub-id pub-id-type="pmid">35446546</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_074"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>M</given-names></name><name name-style="western"><surname>Smbatyan</surname><given-names>G</given-names></name><name name-style="western"><surname>Lenz</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Reprogramming exosomes as nanoscale controllers of cellular immunity</article-title><source>J Am Chem Soc</source><year>2018</year><volume>140</volume><fpage>16413</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b10047</pub-id><pub-id pub-id-type="pmid">30452238</pub-id><pub-id pub-id-type="pmcid">PMC6469991</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_075"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmides</surname><given-names>AK</given-names></name><name name-style="western"><surname>Sidhom</surname><given-names>JW</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>A</given-names></name><name name-style="western"><surname>Bessell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>JP</given-names></name></person-group><article-title>Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>5417</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b08152</pub-id><pub-id pub-id-type="pmid">28589725</pub-id><pub-id pub-id-type="pmcid">PMC8635119</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_076"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YN</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>1359</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-21497-6</pub-id><pub-id pub-id-type="pmid">33649336</pub-id><pub-id pub-id-type="pmcid">PMC7921676</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_077"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majmudar</surname><given-names>MD</given-names></name><name name-style="western"><surname>Keliher</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Heidt</surname><given-names>T</given-names></name><name name-style="western"><surname>Leuschner</surname><given-names>F</given-names></name><name name-style="western"><surname>Truelove</surname><given-names>J</given-names></name><name name-style="western"><surname>Sena</surname><given-names>BF</given-names></name><etal/></person-group><article-title>Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice</article-title><source>Circulation</source><year>2013</year><volume>127</volume><fpage>2038</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.112.000116</pub-id><pub-id pub-id-type="pmid">23616627</pub-id><pub-id pub-id-type="pmcid">PMC3661714</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_078"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Cationic polymeric nanoparticle delivering CCR2 siRNA to inflammatory monocytes for tumor microenvironment modification and cancer therapy</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><fpage>3642</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00997</pub-id><pub-id pub-id-type="pmid">29337566</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_079"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Dai</surname><given-names>B</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>9536</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b05465</pub-id><pub-id pub-id-type="pmid">28858473</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_080"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Yang</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Lian</surname><given-names>ZX</given-names></name><etal/></person-group><article-title>Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy</article-title><source>Nano Lett</source><year>2017</year><volume>17</volume><fpage>3822</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.7b01193</pub-id><pub-id pub-id-type="pmid">28488871</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_082"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conde</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>C</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>ER</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Dual targeted immunotherapy via in&#160;vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells</article-title><source>Adv Funct Mater</source><year>2015</year><volume>25</volume><fpage>4183</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/adfm.201501283</pub-id><pub-id pub-id-type="pmid">27340392</pub-id><pub-id pub-id-type="pmcid">PMC4914053</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_088"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>CT</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>DK</given-names></name><name name-style="western"><surname>Ye</surname><given-names>QN</given-names></name><name name-style="western"><surname>Liao</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells</article-title><source>Nano Today</source><year>2021</year><volume>39</volume><elocation-id>101209</elocation-id><pub-id pub-id-type="doi">10.1016/j.nantod.2021.101209</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_081"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Precise depletion of tumor seed and growing soil with shrinkable nanocarrier for potentiated cancer chemoimmunotherapy</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><fpage>4636</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c08996</pub-id><pub-id pub-id-type="pmid">33651592</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_083"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in&#160;vivo</article-title><source>Nanoscale</source><year>2020</year><volume>12</volume><fpage>130</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1039/c9nr06505a</pub-id><pub-id pub-id-type="pmid">31799577</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_084"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awojoodu</surname><given-names>AO</given-names></name><name name-style="western"><surname>Ogle</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sefcik</surname><given-names>LS</given-names></name><name name-style="western"><surname>Bowers</surname><given-names>DT</given-names></name><name name-style="western"><surname>Martin</surname><given-names>K</given-names></name><name name-style="western"><surname>Brayman</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis</article-title><source>Proc Natl Acad Sci U S A</source><year>2013</year><volume>110</volume><fpage>13785</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1073/pnas.1221309110</pub-id><pub-id pub-id-type="pmid">23918395</pub-id><pub-id pub-id-type="pmcid">PMC3752259</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_085"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harel-Adar</surname><given-names>T</given-names></name><name name-style="western"><surname>Mordechai</surname><given-names>TB</given-names></name><name name-style="western"><surname>Amsalem</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Leor</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S</given-names></name></person-group><article-title>Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>1827</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015623108</pub-id><pub-id pub-id-type="pmid">21245355</pub-id><pub-id pub-id-type="pmcid">PMC3033268</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_086"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment</article-title><source>Nat Nanotechnol</source><year>2019</year><volume>14</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1038/s41565-018-0319-4</pub-id><pub-id pub-id-type="pmid">30531990</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_087"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>A</given-names></name><name name-style="western"><surname>Chandrasekar</surname><given-names>V</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ramesh</surname><given-names>A</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>P</given-names></name><name name-style="western"><surname>Nirgud</surname><given-names>J</given-names></name><etal/></person-group><article-title>A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer</article-title><source>Nat Biomed Eng</source><year>2018</year><volume>2</volume><fpage>589</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/s41551-018-0254-6</pub-id><pub-id pub-id-type="pmid">30956894</pub-id><pub-id pub-id-type="pmcid">PMC6450396</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_089"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H</given-names></name><name name-style="western"><surname>Wei</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>1078</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b08872</pub-id><pub-id pub-id-type="pmid">30608136</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_090"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H-Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J</given-names></name><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H-K</given-names></name><etal/></person-group><article-title>Use of macrophages to deliver therapeutic and imaging contrast agents to tumors</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>4195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.02.022</pub-id><pub-id pub-id-type="pmid">22398206</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_091"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Bioengineered macrophages can responsively transform into nanovesicles to target lung metastasis</article-title><source>Nano Lett</source><year>2018</year><volume>18</volume><fpage>4762</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.8b01236</pub-id><pub-id pub-id-type="pmid">30028623</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_092"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Responsive exosome nano-bioconjugates for synergistic cancer therapy</article-title><source>Angew Chem Int Ed Engl</source><year>2020</year><volume>59</volume><fpage>2018</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/ange.201912524</pub-id><pub-id pub-id-type="pmid">31746532</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_093"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenbarth</surname><given-names>SC</given-names></name></person-group><article-title>Dendritic cell subsets in T&#160;cell programming: location dictates function</article-title><source>Nat Rev Immunol</source><year>2019</year><volume>19</volume><fpage>89</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0088-1</pub-id><pub-id pub-id-type="pmid">30464294</pub-id><pub-id pub-id-type="pmcid">PMC7755085</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_094"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinkernagel</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ehl</surname><given-names>S</given-names></name><name name-style="western"><surname>Aichele</surname><given-names>P</given-names></name><name name-style="western"><surname>Oehen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kundig</surname><given-names>T</given-names></name><name name-style="western"><surname>Hengartner</surname><given-names>H</given-names></name></person-group><article-title>Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity</article-title><source>Immunol Rev</source><year>1997</year><volume>156</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065x.1997.tb00969.x</pub-id><pub-id pub-id-type="pmid">9176709</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_095"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinman</surname><given-names>RM</given-names></name></person-group><article-title>The control of immunity and tolerance by dendritic cells</article-title><source>Pathol Biol</source><year>2003</year><volume>51</volume><fpage>59</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/s0369-8114(03)00096-8</pub-id><pub-id pub-id-type="pmid">12801800</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_096"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanna</surname><given-names>MY</given-names></name><name name-style="western"><surname>Yasmin</surname><given-names>AR</given-names></name><name name-style="western"><surname>Omar</surname><given-names>AR</given-names></name><name name-style="western"><surname>Arshad</surname><given-names>SS</given-names></name><name name-style="western"><surname>Mariatulqabtiah</surname><given-names>AR</given-names></name><name name-style="western"><surname>Nur-Fazila</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Review of dendritic cells, their role in clinical immunology, and distribution in various animal species</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>8044</fpage><pub-id pub-id-type="doi">10.3390/ijms22158044</pub-id><pub-id pub-id-type="pmid">34360810</pub-id><pub-id pub-id-type="pmcid">PMC8348663</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_097"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>YN</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Cationic lipid&#8211;assisted nanoparticles for delivery of mRNA cancer vaccine</article-title><source>Biomater Sci</source><year>2018</year><volume>6</volume><fpage>3009</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1039/c8bm00908b</pub-id><pub-id pub-id-type="pmid">30264063</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_098"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H-B</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y-L</given-names></name><etal/></person-group><article-title>In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance</article-title><source>Biomaterials</source><year>2019</year><volume>217</volume><elocation-id>119302</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119302</pub-id><pub-id pub-id-type="pmid">31271858</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_099"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Liang</surname><given-names>LF</given-names></name><name name-style="western"><surname>Gan</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YN</given-names></name><etal/></person-group><article-title>An all-in-one nanomedicine consisting of CRISPR-Cas9 and an autoantigen peptide for restoring specific immune tolerance</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><fpage>48259</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c10885</pub-id><pub-id pub-id-type="pmid">33070614</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleh</surname><given-names>A</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>S</given-names></name><name name-style="western"><surname>Tekin</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>R</given-names></name></person-group><article-title>Vaccine development throughout history</article-title><source>Cureus</source><year>2021</year><volume>13</volume><elocation-id>e16635</elocation-id><pub-id pub-id-type="doi">10.7759/cureus.16635</pub-id><pub-id pub-id-type="pmid">34462676</pub-id><pub-id pub-id-type="pmcid">PMC8386248</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimp</surname><given-names>RL</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>C</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Vu</surname><given-names>N</given-names></name><name name-style="western"><surname>Aebig</surname><given-names>J</given-names></name><etal/></person-group><article-title>Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>2954</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.04.034</pub-id><pub-id pub-id-type="pmid">23623858</pub-id><pub-id pub-id-type="pmcid">PMC3683851</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Muratova</surname><given-names>O</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Dobrescu</surname><given-names>G</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>3923</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.02.073</pub-id><pub-id pub-id-type="pmid">17428587</pub-id><pub-id pub-id-type="pmcid">PMC1940062</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Sagaseta</surname><given-names>J</given-names></name><name name-style="western"><surname>Malito</surname><given-names>E</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Bottomley</surname><given-names>MJ</given-names></name></person-group><article-title>Self-assembling protein nanoparticles in the design of vaccines</article-title><source>Comput Struct Biotechnol J</source><year>2016</year><volume>14</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2015.11.001</pub-id><pub-id pub-id-type="pmid">26862374</pub-id><pub-id pub-id-type="pmcid">PMC4706605</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brune</surname><given-names>KD</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M</given-names></name></person-group><article-title>New Routes and opportunities for modular construction of particulate vaccines: stick, click, and glue</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1432</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01432</pub-id><pub-id pub-id-type="pmid">29997617</pub-id><pub-id pub-id-type="pmcid">PMC6028521</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chackerian</surname><given-names>B</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>DR</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name></person-group><article-title>Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>415</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1172/jci11849</pub-id><pub-id pub-id-type="pmid">11489935</pub-id><pub-id pub-id-type="pmcid">PMC209354</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Dichwalkar</surname><given-names>T</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JY</given-names></name><name name-style="western"><surname>Cossette</surname><given-names>B</given-names></name><name name-style="western"><surname>Garafola</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>AQ</given-names></name><etal/></person-group><article-title>Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1126/science.aav8692</pub-id><pub-id pub-id-type="pmid">31296767</pub-id><pub-id pub-id-type="pmcid">PMC6800571</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_112"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Gao</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses</article-title><source>J&#160;Contr Release</source><year>2013</year><volume>168</volume><fpage>271</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.03.025</pub-id><pub-id pub-id-type="pmid">23562637</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_107"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tokatlian</surname><given-names>T</given-names></name><name name-style="western"><surname>Read</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>DW</given-names></name><name name-style="western"><surname>Menis</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers</article-title><source>Science</source><year>2019</year><volume>363</volume><fpage>649</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1126/science.aat9120</pub-id><pub-id pub-id-type="pmid">30573546</pub-id><pub-id pub-id-type="pmcid">PMC6420719</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_108"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>JT</given-names></name></person-group><article-title>A sweeter approach to vaccine design</article-title><source>Science</source><year>2019</year><volume>363</volume><fpage>584</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.aav9000</pub-id><pub-id pub-id-type="pmid">30733404</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_109"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>NK</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>RV</given-names></name><name name-style="western"><surname>Soleimany</surname><given-names>AP</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Rothschilds</surname><given-names>AM</given-names></name><name name-style="western"><surname>Momin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines</article-title><source>Nat Biomed Eng</source><year>2020</year><volume>4</volume><fpage>636</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-0563-4</pub-id><pub-id pub-id-type="pmid">32483299</pub-id><pub-id pub-id-type="pmcid">PMC7575059</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_110"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsopelas</surname><given-names>C</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>R</given-names></name></person-group><article-title>Why certain dyes are useful for localizing the sentinel lymph node</article-title><source>J Nucl Med</source><year>2002</year><volume>43</volume><fpage>1377</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12368377</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_111"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>GL</given-names></name><name name-style="western"><surname>Li</surname><given-names>AV</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Structure-based programming of lymph-node targeting in molecular vaccines</article-title><source>Nature</source><year>2014</year><volume>507</volume><fpage>519</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/nature12978</pub-id><pub-id pub-id-type="pmid">24531764</pub-id><pub-id pub-id-type="pmcid">PMC4069155</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boczkowski</surname><given-names>D</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SK</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>D</given-names></name><name name-style="western"><surname>Gilboa</surname><given-names>E</given-names></name></person-group><article-title>Dendritic cells pulsed with RNA are potent antigen-presenting cells in&#160;vitro and in&#160;vivo</article-title><source>J Exp Med</source><year>1996</year><volume>184</volume><fpage>465</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1084/jem.184.2.465</pub-id><pub-id pub-id-type="pmid">8760800</pub-id><pub-id pub-id-type="pmcid">PMC2192710</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Z-D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y-F</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C-F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Co-delivery of phagocytosis checkpoint silencer and stimulator of interferon genes agonist for synergetic cancer immunotherapy</article-title><source>ACS Appl Mater Interfaces</source><year>2021</year><volume>13</volume><fpage>29424</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c08329</pub-id><pub-id pub-id-type="pmid">34129318</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>C</given-names></name><name name-style="western"><surname>Rawat</surname><given-names>A</given-names></name><name name-style="western"><surname>Hope-Weeks</surname><given-names>L</given-names></name><name name-style="western"><surname>Ahsan</surname><given-names>F</given-names></name></person-group><article-title>Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine</article-title><source>Mol Pharm</source><year>2011</year><volume>8</volume><fpage>405</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1021/mp100255c</pub-id><pub-id pub-id-type="pmid">21189035</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diwan</surname><given-names>M</given-names></name><name name-style="western"><surname>Tafaghodi</surname><given-names>M</given-names></name><name name-style="western"><surname>Samuel</surname><given-names>J</given-names></name></person-group><article-title>Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres</article-title><source>J Contr Release</source><year>2002</year><volume>85</volume><fpage>247</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/s0168-3659(02)00275-4</pub-id><pub-id pub-id-type="pmid">12480329</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Cody</surname><given-names>V</given-names></name><name name-style="western"><surname>Giodini</surname><given-names>A</given-names></name><name name-style="western"><surname>Hinson</surname><given-names>ER</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P</given-names></name><etal/></person-group><article-title>Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles</article-title><source>Immunology</source><year>2006</year><volume>117</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02268.x</pub-id><pub-id pub-id-type="pmid">16423043</pub-id><pub-id pub-id-type="pmcid">PMC1782199</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanchan</surname><given-names>V</given-names></name><name name-style="western"><surname>Katare</surname><given-names>YK</given-names></name><name name-style="western"><surname>Panda</surname><given-names>AK</given-names></name></person-group><article-title>Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics</article-title><source>Biomaterials</source><year>2009</year><volume>30</volume><fpage>4763</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.05.075</pub-id><pub-id pub-id-type="pmid">19540583</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baras</surname><given-names>B</given-names></name><name name-style="western"><surname>Benoit</surname><given-names>MA</given-names></name><name name-style="western"><surname>Dupre</surname><given-names>L</given-names></name><name name-style="western"><surname>Poulain-Godefroy</surname><given-names>O</given-names></name><name name-style="western"><surname>Schacht</surname><given-names>AM</given-names></name><name name-style="western"><surname>Capron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen</article-title><source>Infect Immun</source><year>1999</year><volume>67</volume><fpage>2643</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1128/iai.67.5.2643-2648.1999</pub-id><pub-id pub-id-type="pmid">10225935</pub-id><pub-id pub-id-type="pmcid">PMC116018</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant</article-title><source>Eur J Pharmaceut Sci</source><year>2011</year><volume>44</volume><fpage>653</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.012</pub-id><pub-id pub-id-type="pmid">22064451</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment</article-title><source>Nano Lett</source><year>2012</year><volume>12</volume><fpage>2003</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1021/nl300027p</pub-id><pub-id pub-id-type="pmid">22372996</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>W</given-names></name><name name-style="western"><surname>Gill</surname><given-names>HS</given-names></name></person-group><article-title>M2e-immobilized gold nanoparticles as influenza A vaccine: role of soluble M2e and longevity of protection</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>2307</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.063</pub-id><pub-id pub-id-type="pmid">25842219</pub-id><pub-id pub-id-type="pmcid">PMC4418433</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Silica nanoparticle as a lymph node targeting platform for vaccine delivery</article-title><source>ACS Appl Mater Interfaces</source><year>2017</year><volume>9</volume><fpage>23466</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b06024</pub-id><pub-id pub-id-type="pmid">28640587</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Suh</surname><given-names>H</given-names></name><name name-style="western"><surname>Bershteyn</surname><given-names>A</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>MT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses</article-title><source>Nat Mater</source><year>2011</year><volume>10</volume><fpage>243</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nmat2960</pub-id><pub-id pub-id-type="pmid">21336265</pub-id><pub-id pub-id-type="pmcid">PMC3077947</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichihashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>C</given-names></name><name name-style="western"><surname>Kajino</surname><given-names>K</given-names></name></person-group><article-title>Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T&#160;cell responses</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><elocation-id>e60068</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0060068</pub-id><pub-id pub-id-type="pmid">23533665</pub-id><pub-id pub-id-type="pmcid">PMC3606214</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>LM</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature18300</pub-id><pub-id pub-id-type="pmid">27281205</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M</given-names></name><name name-style="western"><surname>Kloke</surname><given-names>BP</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P</given-names></name><name name-style="western"><surname>Loewer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>222</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilkens</surname><given-names>CMU</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>JD</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>AW</given-names></name></person-group><article-title>Development of dendritic cell-based immunotherapy for autoimmunity</article-title><source>Int Rev Immunol</source><year>2010</year><volume>29</volume><fpage>156</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3109/08830180903281193</pub-id><pub-id pub-id-type="pmid">20199240</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krienke</surname><given-names>C</given-names></name><name name-style="western"><surname>Kolb</surname><given-names>L</given-names></name><name name-style="western"><surname>Diken</surname><given-names>E</given-names></name><name name-style="western"><surname>Streuber</surname><given-names>M</given-names></name><name name-style="western"><surname>Kirchhoff</surname><given-names>S</given-names></name><name name-style="western"><surname>Bukur</surname><given-names>T</given-names></name><etal/></person-group><article-title>A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.aay3638</pub-id><pub-id pub-id-type="pmid">33414215</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wardell</surname><given-names>CM</given-names></name><name name-style="western"><surname>Levings</surname><given-names>MK</given-names></name></person-group><article-title>mRNA vaccines take on immune tolerance</article-title><source>Nat Biotechnol</source><year>2021</year><volume>39</volume><fpage>419</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41587-021-00880-0</pub-id><pub-id pub-id-type="pmid">33785909</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mucker</surname><given-names>EM</given-names></name><name name-style="western"><surname>Karmali</surname><given-names>PP</given-names></name><name name-style="western"><surname>Vega</surname><given-names>J</given-names></name><name name-style="western"><surname>Kwilas</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Joselyn</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>8764</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-65059-0</pub-id><pub-id pub-id-type="pmid">32472093</pub-id><pub-id pub-id-type="pmcid">PMC7260227</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_146"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name></person-group><article-title>Nanocarriers based on bacterial membrane materials for cancer vaccine delivery</article-title><source>Nat Protoc</source><year>2022</year><volume>17</volume><fpage>2240</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/s41596-022-00713-7</pub-id><pub-id pub-id-type="pmid">35879454</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_132"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banskota</surname><given-names>S</given-names></name><name name-style="western"><surname>Raguram</surname><given-names>A</given-names></name><name name-style="western"><surname>Suh</surname><given-names>S</given-names></name><name name-style="western"><surname>Du</surname><given-names>SW</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JR</given-names></name><name name-style="western"><surname>Choi</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Engineered virus-like particles for efficient in&#160;vivo delivery of therapeutic proteins</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>250</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.12.021</pub-id><pub-id pub-id-type="pmid">35021064</pub-id><pub-id pub-id-type="pmcid">PMC8809250</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_133"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tariq</surname><given-names>H</given-names></name><name name-style="western"><surname>Batool</surname><given-names>S</given-names></name><name name-style="western"><surname>Asif</surname><given-names>S</given-names></name><name name-style="western"><surname>Ali</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>BH</given-names></name></person-group><article-title>Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases</article-title><source>Front Microbiol</source><year>2022</year><volume>12</volume><elocation-id>790121</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.790121</pub-id><pub-id pub-id-type="pmid">35046918</pub-id><pub-id pub-id-type="pmcid">PMC8761975</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_134"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tsybovsky</surname><given-names>Y</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>K</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S</given-names></name><etal/></person-group><article-title>A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>2234</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01574-5</pub-id><pub-id pub-id-type="pmid">34887575</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_135"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Beales</surname><given-names>L</given-names></name><name name-style="western"><surname>Peyret</surname><given-names>H</given-names></name><name name-style="western"><surname>Roe</surname><given-names>A</given-names></name><name name-style="western"><surname>Stonehouse</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>DJ</given-names></name></person-group><article-title>Recombinant expression of tandem-HBc virus-like particles (VLPs)</article-title><source>Methods Mol Biol</source><year>2018</year><volume>1776</volume><fpage>97</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7808-3_7</pub-id><pub-id pub-id-type="pmid">29869237</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_136"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohsen</surname><given-names>MO</given-names></name><name name-style="western"><surname>Zha</surname><given-names>L</given-names></name><name name-style="western"><surname>Cabral-Miranda</surname><given-names>G</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>MF</given-names></name></person-group><article-title>Major findings and recent advances in virus like particle (VLP)-based vaccines</article-title><source>Semin Immunol</source><year>2017</year><volume>34</volume><fpage>123</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2017.08.014</pub-id><pub-id pub-id-type="pmid">28887001</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_137"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefanetti</surname><given-names>G</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Micoli</surname><given-names>F</given-names></name></person-group><article-title>Click chemistry applied to the synthesis of salmonella typhimurium O-antigen glycoconjugate vaccine on solid phase with sugar recycling</article-title><source>Bioconjugate Chem</source><year>2015</year><volume>26</volume><fpage>2507</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.5b00521</pub-id><pub-id pub-id-type="pmid">26549104</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_138"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooraei</surname><given-names>S</given-names></name><name name-style="western"><surname>Bahrulolum</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoseini</surname><given-names>ZS</given-names></name><name name-style="western"><surname>Katalani</surname><given-names>C</given-names></name><name name-style="western"><surname>Hajizade</surname><given-names>A</given-names></name><name name-style="western"><surname>Easton</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id><pub-id pub-id-type="pmcid">PMC7905985</pub-id><pub-id pub-id-type="pmid">33632278</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_139"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>QZ</given-names></name><name name-style="western"><surname>Kuhlmann</surname><given-names>FM</given-names></name><name name-style="western"><surname>Eller</surname><given-names>R</given-names></name><name name-style="western"><surname>Compans</surname><given-names>RW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>Production and characterization of simian-human immunodeficiency virus-like particles</article-title><source>AIDS Res Hum Retrovir</source><year>2000</year><volume>16</volume><fpage>227</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1089/088922200309322</pub-id><pub-id pub-id-type="pmid">10710211</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_140"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetzel</surname><given-names>D</given-names></name><name name-style="western"><surname>Barbian</surname><given-names>A</given-names></name><name name-style="western"><surname>Jenzelewski</surname><given-names>V</given-names></name><name name-style="western"><surname>Schembecker</surname><given-names>G</given-names></name><name name-style="western"><surname>Merz</surname><given-names>J</given-names></name><name name-style="western"><surname>Piontek</surname><given-names>M</given-names></name></person-group><article-title>Bioprocess optimization for purification of chimeric VLP displaying BVDV E2 antigens produced in yeast Hansenula polymorpha</article-title><source>J Biotechnol</source><year>2019</year><volume>306</volume><fpage>203</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2019.10.008</pub-id><pub-id pub-id-type="pmid">31634510</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_141"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keikha</surname><given-names>R</given-names></name><name name-style="western"><surname>Daliri</surname><given-names>K</given-names></name><name name-style="western"><surname>Jebali</surname><given-names>A</given-names></name></person-group><article-title>The use of nanobiotechnology in immunology and vaccination</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.3390/vaccines9020074</pub-id><pub-id pub-id-type="pmid">33494441</pub-id><pub-id pub-id-type="pmcid">PMC7910821</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_142"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naskalska</surname><given-names>A</given-names></name><name name-style="western"><surname>Pyrc</surname><given-names>K</given-names></name></person-group><article-title>Virus like particles as immunogens and universal nanocarriers</article-title><source>Pol J Microbiol</source><year>2015</year><volume>64</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.33073/pjm-2015-001</pub-id><pub-id pub-id-type="pmid">26094310</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_143"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Bahjat</surname><given-names>KS</given-names></name><name name-style="western"><surname>Schwendeman</surname><given-names>A</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JJ</given-names></name></person-group><article-title>Designer vaccine nanodiscs for personalized cancer immunotherapy</article-title><source>Nat Mater</source><year>2017</year><volume>16</volume><fpage>489</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/nmat4822</pub-id><pub-id pub-id-type="pmid">28024156</pub-id><pub-id pub-id-type="pmcid">PMC5374005</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_144"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A DNA nanodevice-based vaccine for cancer immunotherapy</article-title><source>Nat Mater</source><year>2021</year><volume>20</volume><fpage>431</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0793-6</pub-id><pub-id pub-id-type="pmid">32939052</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_145"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy</article-title><source>Nat Nanotechnol</source><year>2022</year><volume>17</volume><fpage>531</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01098-0</pub-id><pub-id pub-id-type="pmid">35410368</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Miao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name></person-group><article-title>Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity</article-title><source>Nano Today</source><year>2020</year><volume>35</volume><elocation-id>101007</elocation-id><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101007</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobukai</surname><given-names>S</given-names></name><name name-style="western"><surname>Baheza</surname><given-names>R</given-names></name><name name-style="western"><surname>Cobb</surname><given-names>JG</given-names></name><name name-style="western"><surname>Virostko</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Gillman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Magnetic nanoparticles for imaging dendritic cells</article-title><source>Magn Reson Med</source><year>2010</year><volume>63</volume><fpage>1383</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/mrm.22313</pub-id><pub-id pub-id-type="pmid">20432309</pub-id><pub-id pub-id-type="pmcid">PMC4888962</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#233;meth</surname><given-names>T</given-names></name><name name-style="western"><surname>Sperandio</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#243;csai</surname><given-names>A</given-names></name></person-group><article-title>Neutrophils as emerging therapeutic targets</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><fpage>253</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0054-z</pub-id><pub-id pub-id-type="pmid">31969717</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burn</surname><given-names>GL</given-names></name><name name-style="western"><surname>Foti</surname><given-names>A</given-names></name><name name-style="western"><surname>Marsman</surname><given-names>G</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DF</given-names></name><name name-style="western"><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><article-title>The neutrophil</article-title><source>Immunity</source><year>2021</year><volume>54</volume><fpage>1377</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.06.006</pub-id><pub-id pub-id-type="pmid">34260886</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papayannopoulos</surname><given-names>V</given-names></name></person-group><article-title>Neutrophil extracellular traps in immunity and disease</article-title><source>Nat Rev Immunol</source><year>2018</year><volume>18</volume><fpage>134</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.105</pub-id><pub-id pub-id-type="pmid">28990587</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wigerblad</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>MJ</given-names></name></person-group><article-title>Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases</article-title><source>Nat Rev Immunol</source><year>2022</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00787-0</pub-id><pub-id pub-id-type="pmid">36257987</pub-id><pub-id pub-id-type="pmcid">PMC9579530</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaillon</surname><given-names>S</given-names></name><name name-style="western"><surname>Ponzetta</surname><given-names>A</given-names></name><name name-style="western"><surname>Di Mitri</surname><given-names>D</given-names></name><name name-style="western"><surname>Santoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonecchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Neutrophil diversity and plasticity in tumour progression and therapy</article-title><source>Nat Rev Cancer</source><year>2020</year><volume>20</volume><fpage>485</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0281-y</pub-id><pub-id pub-id-type="pmid">32694624</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>O</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Targeting neutrophils for enhanced cancer theranostics</article-title><source>Adv Mater</source><year>2020</year><volume>32</volume><elocation-id>e2002739</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202002739</pub-id><pub-id pub-id-type="pmid">32656801</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedrick</surname><given-names>CC</given-names></name><name name-style="western"><surname>Malanchi</surname><given-names>I</given-names></name></person-group><article-title>Neutrophils in cancer: heterogeneous and multifaceted</article-title><source>Nat Rev Immunol</source><year>2022</year><volume>22</volume><fpage>173</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00571-6</pub-id><pub-id pub-id-type="pmid">34230649</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>1126</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14963-0</pub-id><pub-id pub-id-type="pmid">32111847</pub-id><pub-id pub-id-type="pmcid">PMC7048836</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Ding</surname><given-names>S</given-names></name><etal/></person-group><article-title>Voluntary-opsonization-enabled precision nanomedicines for inflammation treatment</article-title><source>Adv Mater</source><year>2021</year><volume>33</volume><elocation-id>e2006160</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202006160</pub-id><pub-id pub-id-type="pmid">33296121</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nanotechnology reinforced neutrophil-based therapeutic strategies for inflammatory diseases therapy</article-title><source>Nano Today</source><year>2022</year><volume>46</volume><elocation-id>101577</elocation-id><pub-id pub-id-type="doi">10.1016/j.nantod.2022.101577</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lu</surname><given-names>ZD</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Optimization of lipid-assisted nanoparticle for disturbing neutrophils-related inflammation</article-title><source>Biomaterials</source><year>2018</year><volume>172</volume><fpage>92</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.04.052</pub-id><pub-id pub-id-type="pmid">29723758</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_162"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ju</surname><given-names>C</given-names></name><etal/></person-group><article-title>Recognition, intervention, and monitoring of neutrophils in acute ischemic stroke</article-title><source>Nano Lett</source><year>2019</year><volume>19</volume><fpage>4470</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b01282</pub-id><pub-id pub-id-type="pmid">31244234</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_160"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bohinc</surname><given-names>D</given-names></name><name name-style="western"><surname>Andraska</surname><given-names>EA</given-names></name><name name-style="western"><surname>Alvikas</surname><given-names>J</given-names></name><name name-style="western"><surname>Raghunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Masters</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an alpha(1)-antitrypsin-derived peptide motif</article-title><source>Nat Nanotechnol</source><year>2022</year><volume>17</volume><fpage>1004</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01161-w</pub-id><pub-id pub-id-type="pmid">35851383</pub-id><pub-id pub-id-type="pmcid">PMC9909445</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_161"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>K</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hesperetin nanoparticle targeting neutrophils for enhanced TBI therapy</article-title><source>Adv Funct Mater</source><year>2022</year><volume>32</volume><elocation-id>2205787</elocation-id><pub-id pub-id-type="doi">10.1002/adfm.202205787</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence</article-title><source>Nat Nanotechnol</source><year>2017</year><volume>12</volume><fpage>692</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/nnano.2017.54</pub-id><pub-id pub-id-type="pmid">28650441</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy</article-title><source>Biomaterials</source><year>2021</year><volume>273</volume><elocation-id>120784</elocation-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120784</pub-id><pub-id pub-id-type="pmid">33848731</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><name name-style="western"><surname>Mao</surname><given-names>F</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy</article-title><source>Sci Adv</source><year>2022</year><volume>8</volume><elocation-id>eabj8207</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abj8207</pub-id><pub-id pub-id-type="pmid">35020437</pub-id><pub-id pub-id-type="pmcid">PMC8754405</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dehaini</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis</article-title><source>Nat Nanotechnol</source><year>2018</year><volume>13</volume><fpage>1182</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s41565-018-0254-4</pub-id><pub-id pub-id-type="pmid">30177807</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Targeting drugs to tumours using cell membrane-coated nanoparticles</article-title><source>Nat Rev Clin Oncol</source><year>2022</year><volume>20</volume><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00699-x</pub-id><pub-id pub-id-type="pmid">36307534</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>M</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy</article-title><source>Nano Lett</source><year>2020</year><volume>20</volume><fpage>242</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b03753</pub-id><pub-id pub-id-type="pmid">31790598</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A fibrin site-specific nanoprobe for imaging fibrin-rich thrombi and preventing thrombus formation in venous vessels</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><elocation-id>e2109955</elocation-id><pub-id pub-id-type="doi">10.1002/adma.202109955</pub-id><pub-id pub-id-type="pmid">35194836</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>FcRn-targeting and ROS-responsive Fedratinib-incorporated nanoparticles alleviate asthma by inducing eosinophil apoptosis</article-title><source>Allergy</source><year>2022</year><pub-id pub-id-type="doi">10.1111/all.15575</pub-id><pub-id pub-id-type="pmid">36325826</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claes</surname><given-names>N</given-names></name><name name-style="western"><surname>Fraussen</surname><given-names>J</given-names></name><name name-style="western"><surname>Stinissen</surname><given-names>P</given-names></name><name name-style="western"><surname>Hupperts</surname><given-names>R</given-names></name><name name-style="western"><surname>Somers</surname><given-names>V</given-names></name></person-group><article-title>B&#160;cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>642</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00642</pub-id><pub-id pub-id-type="pmid">26734009</pub-id><pub-id pub-id-type="pmcid">PMC4685142</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castiglioni</surname><given-names>P</given-names></name><name name-style="western"><surname>Gerloni</surname><given-names>M</given-names></name><name name-style="western"><surname>Zanetti</surname><given-names>M</given-names></name></person-group><article-title>Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T&#160;cells</article-title><source>Vaccine</source><year>2004</year><volume>23</volume><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.028</pub-id><pub-id pub-id-type="pmid">15542193</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>SJS</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>MS</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>WH</given-names></name></person-group><article-title>B&#160;cell checkpoints in autoimmune rheumatic diseases</article-title><source>Nat Rev Rheumatol</source><year>2019</year><volume>15</volume><fpage>303</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41584-019-0211-0</pub-id><pub-id pub-id-type="pmid">30967621</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YN</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Lian</surname><given-names>ZX</given-names></name><etal/></person-group><article-title>Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B&#160;cell intervention</article-title><source>Nano Res</source><year>2018</year><volume>11</volume><fpage>6270</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1007/s12274-018-2150-5</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>ZQ</given-names></name><name name-style="western"><surname>Cao</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Nanoparticle-delivered siRNA targeting Bruton&#8217;s tyrosine kinase for rheumatoid arthritis therapy</article-title><source>Biomater Sci</source><year>2019</year><volume>7</volume><fpage>4698</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1039/c9bm01025d</pub-id><pub-id pub-id-type="pmid">31495833</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_182"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingale</surname><given-names>J</given-names></name><name name-style="western"><surname>Stano</surname><given-names>A</given-names></name><name name-style="western"><surname>Guenaga</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>SK</given-names></name><name name-style="western"><surname>Nemazee</surname><given-names>D</given-names></name><name name-style="western"><surname>Zwick</surname><given-names>MB</given-names></name><etal/></person-group><article-title>High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B&#160;cells</article-title><source>Cell Rep</source><year>2016</year><volume>15</volume><fpage>1986</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.078</pub-id><pub-id pub-id-type="pmid">27210756</pub-id><pub-id pub-id-type="pmcid">PMC4889521</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_176"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name></person-group><article-title>Eliciting B&#160;cell immunity against infectious diseases using nanovaccines</article-title><source>Nat Nanotechnol</source><year>2021</year><volume>16</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00790-3</pub-id><pub-id pub-id-type="pmid">33199883</pub-id><pub-id pub-id-type="pmcid">PMC7855692</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_177"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temchura</surname><given-names>VV</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>D</given-names></name><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>Ueberla</surname><given-names>K</given-names></name><name name-style="western"><surname>Epple</surname><given-names>M</given-names></name></person-group><article-title>Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>6098</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.010</pub-id><pub-id pub-id-type="pmid">24776487</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_178"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zilker</surname><given-names>C</given-names></name><name name-style="western"><surname>Kozlova</surname><given-names>D</given-names></name><name name-style="western"><surname>Sokolova</surname><given-names>V</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H</given-names></name><name name-style="western"><surname>Epple</surname><given-names>M</given-names></name><name name-style="western"><surname>Ueberla</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nanoparticle-based B-cell targeting vaccines: tailoring of humoral immune responses by functionalization with different TLR-ligands</article-title><source>Nanomedicine</source><year>2017</year><volume>13</volume><fpage>173</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2016.08.028</pub-id><pub-id pub-id-type="pmid">27593489</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_179"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>MG</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>JR</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>SF</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B&#160;cell responses</article-title><source>Nat Immunol</source><year>2019</year><volume>20</volume><fpage>362</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0305-x</pub-id><pub-id pub-id-type="pmid">30742080</pub-id><pub-id pub-id-type="pmcid">PMC6380945</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_180"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C-J</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>HM</given-names></name><name name-style="western"><surname>McTamney</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boyington</surname><given-names>JC</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>102</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nature12202</pub-id><pub-id pub-id-type="pmid">23698367</pub-id><pub-id pub-id-type="pmcid">PMC8312026</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_181"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>HG</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H-X</given-names></name><name name-style="western"><surname>Juno</surname><given-names>JA</given-names></name><name name-style="western"><surname>Esterbauer</surname><given-names>R</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B&#160;cell maturation</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><elocation-id>e136653</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136653</pub-id><pub-id pub-id-type="pmid">32434990</pub-id><pub-id pub-id-type="pmcid">PMC7259527</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SH</given-names></name><name name-style="western"><surname>Miyagi</surname><given-names>T</given-names></name><name name-style="western"><surname>Biron</surname><given-names>CA</given-names></name></person-group><article-title>Keeping NK cells in highly regulated antiviral warfare</article-title><source>Trends Immunol</source><year>2007</year><volume>28</volume><fpage>252</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.04.001</pub-id><pub-id pub-id-type="pmid">17466596</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vivier</surname><given-names>E</given-names></name><name name-style="western"><surname>Tomasello</surname><given-names>E</given-names></name><name name-style="western"><surname>Baratin</surname><given-names>M</given-names></name><name name-style="western"><surname>Walzer</surname><given-names>T</given-names></name><name name-style="western"><surname>Ugolini</surname><given-names>S</given-names></name></person-group><article-title>Functions of natural killer cells</article-title><source>Nat Immunol</source><year>2008</year><volume>9</volume><fpage>503</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1038/ni1582</pub-id><pub-id pub-id-type="pmid">18425107</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfefferle</surname><given-names>A</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>B</given-names></name><name name-style="western"><surname>Haroun-Izquierdo</surname><given-names>A</given-names></name><name name-style="western"><surname>Kveberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Sohlberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Malmberg</surname><given-names>KJ</given-names></name></person-group><article-title>Deciphering natural killer cell homeostasis</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>812</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00812</pub-id><pub-id pub-id-type="pmid">32477340</pub-id><pub-id pub-id-type="pmcid">PMC7235169</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Fu</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Shao</surname><given-names>ZM</given-names></name></person-group><article-title>Natural killer cells in cancer biology and therapy</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><fpage>120</fpage><pub-id pub-id-type="doi">10.1186/s12943-020-01238-x</pub-id><pub-id pub-id-type="pmid">32762681</pub-id><pub-id pub-id-type="pmcid">PMC7409673</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ren</surname><given-names>G</given-names></name><name name-style="western"><surname>Park</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>5584</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.04.041</pub-id><pub-id pub-id-type="pmid">22575830</pub-id><pub-id pub-id-type="pmcid">PMC3571620</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H</given-names></name><etal/></person-group><article-title>Magnetic delivery of Fe(3)O(4)@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment</article-title><source>Biomater Sci</source><year>2018</year><volume>6</volume><fpage>2714</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1039/c8bm00588e</pub-id><pub-id pub-id-type="pmid">30151523</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Shou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cell membrane-encapsulated magnetic nanoparticles for enhancing natural killer cell-mediated cancer immunotherapy</article-title><source>Nanomedicine</source><year>2021</year><volume>32</volume><elocation-id>102333</elocation-id><pub-id pub-id-type="doi">10.1016/j.nano.2020.102333</pub-id><pub-id pub-id-type="pmid">33188908</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Park</surname><given-names>JD</given-names></name><name name-style="western"><surname>An</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Cationic nanoparticle-mediated activation of natural killer cells for effective cancer immunotherapy</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><fpage>56731</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c16357</pub-id><pub-id pub-id-type="pmid">33290037</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loftus</surname><given-names>C</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>M</given-names></name><name name-style="western"><surname>Davis</surname><given-names>DM</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>IE</given-names></name></person-group><article-title>Activation of human natural killer cells by graphene oxide-templated antibody nanoclusters</article-title><source>Nano Lett</source><year>2018</year><volume>18</volume><fpage>3282</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.8b01089</pub-id><pub-id pub-id-type="pmid">29676151</pub-id><pub-id pub-id-type="pmcid">PMC5951604</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuroi</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Warashina</surname><given-names>S</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H</given-names></name></person-group><article-title>Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><elocation-id>37849</elocation-id><pub-id pub-id-type="doi">10.1038/srep37849</pub-id><pub-id pub-id-type="pmid">27892533</pub-id><pub-id pub-id-type="pmcid">PMC5124971</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H</given-names></name></person-group><article-title>Reducing the cytotoxicity of lipid nanoparticles associated with a fusogenic cationic lipid in a natural killer cell line by introducing a polycation-based siRNA core</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><fpage>2142</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b01166</pub-id><pub-id pub-id-type="pmid">29668291</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oyer</surname><given-names>JL</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>V</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>RY</given-names></name><name name-style="western"><surname>Somanchi</surname><given-names>SS</given-names></name><name name-style="western"><surname>Zakari</surname><given-names>A</given-names></name><name name-style="western"><surname>Solh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Natural killer cells stimulated with PM21 particles expand and biodistribute in&#160;vivo: clinical implications for cancer treatment</article-title><source>Cytotherapy</source><year>2016</year><volume>18</volume><fpage>653</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jcyt.2016.02.006</pub-id><pub-id pub-id-type="pmid">27059202</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>L</given-names></name><name name-style="western"><surname>Morel</surname><given-names>A</given-names></name><name name-style="western"><surname>Anceriz</surname><given-names>N</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>B</given-names></name><name name-style="western"><surname>Blanchard-Alvarez</surname><given-names>A</given-names></name><name name-style="western"><surname>Grondin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1701</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.041</pub-id><pub-id pub-id-type="pmid">31155232</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Au</surname><given-names>KM</given-names></name><name name-style="western"><surname>Park</surname><given-names>SI</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AZ</given-names></name></person-group><article-title>Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy</article-title><source>Science advance</source><year>2020</year><volume>6</volume><elocation-id>eaba8564</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba8564</pub-id><pub-id pub-id-type="pmcid">PMC7455497</pub-id><pub-id pub-id-type="pmid">32923587</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>MS</given-names></name></person-group><article-title>Immunoengineering: how nanotechnology can enhance cancer immunotherapy</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>201</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.037</pub-id><pub-id pub-id-type="pmid">25860604</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wei</surname><given-names>T</given-names></name><name name-style="western"><surname>Farbiak</surname><given-names>L</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>LT</given-names></name><name name-style="western"><surname>Dilliard</surname><given-names>SA</given-names></name><name name-style="western"><surname>Siegwart</surname><given-names>DJ</given-names></name></person-group><article-title>Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing</article-title><source>Nat Nanotechnol</source><year>2020</year><volume>15</volume><fpage>313</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0669-6</pub-id><pub-id pub-id-type="pmid">32251383</pub-id><pub-id pub-id-type="pmcid">PMC7735425</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaari</surname><given-names>Z</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>D</given-names></name><name name-style="western"><surname>Zinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldman</surname><given-names>E</given-names></name><name name-style="western"><surname>Kajal</surname><given-names>A</given-names></name><name name-style="western"><surname>Tshuva</surname><given-names>R</given-names></name><etal/></person-group><article-title>Theranostic barcoded nanoparticles for personalized cancer medicine</article-title><source>Nat Commun</source><year>2016</year><volume>7</volume><elocation-id>13325</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13325</pub-id><pub-id pub-id-type="pmid">27830705</pub-id><pub-id pub-id-type="pmcid">PMC5109543</pub-id></element-citation></ref><ref id="j_mr-2022-0047_ref_200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>YW</given-names></name><name name-style="western"><surname>Sui</surname><given-names>XZ</given-names></name><name name-style="western"><surname>Song</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>YQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>KY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>2581</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22676-1</pub-id><pub-id pub-id-type="pmid">33972544</pub-id><pub-id pub-id-type="pmcid">PMC8110811</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>